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Type 1 diabetes mellitus (T1D) is an autoimmune disease in which the body’s pancreatic 
β-cells are destroyed through a still incompletely understood immune reaction. β-Cells 
are  highly differentiated neuroendocrine cells that are the only source of the glucose-
regulating hormone insulin in the body. Autoimmune destruction of β cells leads to 
a deficiency of insulin and impaired glucose homeostasis, as without insulin peripheral 
tissues such as fat, liver and skeletal muscle cells are incapable of internalizing glucose 
from the bloodstream. The inability of cells to take up glucose leads to hyperglycemia, 
while leaving tissue cells deprived of their primary energy source. Under normal 
physiological conditions glucose is not present in urine, as it is completely reabsorbed 
in the kidneys. When levels of glucose in the blood surpass the kidney’s reabsorption 
capacity, the excess of glucose is being excreted in the urine, causing  the phenomenon 
from which T1D  derives its name; diabetes mellitus  means honey-sweet flow in 
ancient Greek.  Due to the osmotic effect of glucose in the renal tubules, glycosuria 
causes the concomitant loss of large quantities of water and electrolytes, leading to 
the pathognomonic symptom of polyuria. In turn, polyuria causes dehydration, leading 
to the second pathognomic feature of diabetes mellitus; polydipsia, or excessive thirst. 
In the diabetic state glucose is no longer available as an energy source for peripheral 
tissues and the body reverts to alternative mechanisms of energy production, such as 
the oxidation of fatty acids, to maintain vital cellular processes. During the oxidation of 
fatty acids acidic ketone bodies are produced as a by-product. The loss of circulating 
volume and electrolytes that results from the glycosuria, combined with the increased 
production of acidic ketone bodies can lead to the potentially fatal medical emergency 
known as diabetic ketoacidosis. If the metabolic acidosis  is not corrected swiftly using 
intravenous administration of fluids and exogenous insulin, the condition will lead to coma 
and eventually death.1
T1D is one of the oldest diseases known to medicine, being already described by ancient 
Egyptian physicians in the Eber’s papyrus.2 Despite modern medicine’s familiarity with 
the disease, it has remained an unequivocal death sentence within months after diagnosis 
until 1921, when Banting and Best were the first to isolate insulin from the carcass of a dog . 
This breakthrough paved the way for the first actual treatment for T1D, insulin replacement 
therapy, converting a lethal disease into a chronic condition.  Despite many advances in 
the treatment of T1D over the years, including the development of new insulin analogues, 
improvement in insulin administration and overall better healthcare, insulin replacement 
therapy targets  the  consequences, or symptoms of the disease, and not its cause. T1D 
patients will therefore retain a life-long dependency on exogenous insulin administration 
and remain continuously at risk for the acute complications of insulin replacement therapy, 
i.e. hypoglycemic coma and diabetic ketoacidosis, both potentially fatal conditions on 
their own.3 In addition to the acute complications of their treatment, T1D patients are 
at risk for long-term complications such as ocular, neurological, cardiovascular and renal 
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complications associated with prolonged hyperglycemia, as exogenous insulin cannot 
match the precision of the body’s own mechanisms of glucose regulation.4-6 Further, T1D 
patients often experience reduced quality of life as well as a diminished life expectancy 
despite the best available therapies.3 Elucidation of the exact etiology of T1D is a long 
sought-after goal in modern medicine as it may provide novel targets for a curative 
treatment or even allow prevention of disease. 
Over the course of the 20th century the worldwide incidence of T1D has been on 
the rise  and  is expected to have doubled in children under the age of 5 in the time-period 
from 2005 to 2020.7,8 The cause for this marked rise in incidence remains obscure, but 
given the short time-span in which this increase takes place genetic variability is unlikely 
to be accountable.  Under healthy conditions the human body has an insulin production 
capacity in vast excess of its physiological needs and T1D only becomes clinically overt 
when the insulin production fails to meet the absolute minimum requirements. At time-
of-diagnosis the autoimmune destruction of β-cell often has been ongoing for a long 
time and the majority of β-cell function is already lost. This delay poses difficulties for 
both research as well as potentially curative or preventative treatments as elucidating 
the initiating trigger for disease development long after its onset poses a major challenge. 
Further, β-cells do not appear to have any clinically relevant regeneration rates, reducing 
the chances for T1D patients to regain spontaneous insulin-independence even if 
the autoimmune process could be brought to a halt immediately upon diagnosis of 
the disease.  While increases in pancreatic β-cell mass has been described in conditions of 
increased insulin demand, such as obesity9  and pregnancy10, on average these changes 
are limited. T1D patients often experience a temporal decrease in the need of exogenous 
insulin administration shortly after diagnosis, a period referred to as the honeymoon 
phase. While the existence of this honeymoon phase and the data obtained from obesity 
and pregnancy suggest that (partial) restoration of lost beta cell function is possible, there 
currently are no possibilities to stimulate this response and  the chances for T1D patients 
to regain spontaneous, persistent insulin-independence are slim. Therefore, being able 
to predict disease occurrence by elucidating the factors that predispose to disease may 
facilitate both prediction and  prevention of T1D. 
The estimated lifetime risk for the development of T1D is estimated at 0.4%, but 
geographically a large variation in T1D occurrence exist. Globally, incidence ranges 
from less than 1/100.000 per year in China to over 50/100.000 per year in Finland.7,11 In 
addition to the geographic variation T1D displays aggregation in certain families, causing 
an increased risk of T1D development in individuals with affected parents, siblings or 
offspring.12-14  Children with an affected first-degree family member have a lifetime risk of 
3-8% to develop T1D, but also parents have an increased risk for developing the disease 
themselves as soon a one of their children becomes affected. The actual incidence in 
individuals with an affected first-degree family members depends on many factors, among 
which, but not limited to, ethnicity, family member affected, the age of diagnosis for 




the affected family member and the degree of genetic similarity with the affected family 
member.15-18 In general, children with a diabetic mother  have an estimated risk of 1-4% 
for the development of T1D, while those with an affected father have a lifetime risk of 
3-8%.  This inherited parental risk is multiplicative, rather than additive, and when both 
parents are affected the lifetime risk for their children to develop T1D can be as high as 
30%. In the case of affected siblings, the a-priori risk for disease development ranges 
from 3-6% in case of non-twin siblings, to 8% in dizygotic twins and 30-65% in the case of 
monozygotic twins.19 The proband-wise concordance rate of monozygotic twins is high, 
but no complete, despite their identical genetic makeup. Although the concordance rates 
increase with the number of genetic risk factors present, it does not become  complete, 
suggesting that factors other than genetic variation play a role in T1D development.20-22 
This is indicated as well by the effects of birth order and maternal age at birth, which are 
difficult to explain from a genetic viewpoint, and the fact that the vast majority (>90%) 
of new T1D cases occur in individuals without a family history of the disease. These, 
in addition to genetic susceptibility other factors must be involved in the  onset of β 
cell autoimmunity. Environmental factors such as dietary intake of vitamin D, cow’s milk 
and gluten as well as increased hygienic conditions and viral outbreaks have all been 
implicated as risk modulators, classifying T1D as a complex disease with both genetic and 
environmental factors interacting in its pathogenesis.23-27 
Immunopathology of type 1 diabetes
During evolution, the immune system has adapted to protect the body against a plethora 
of possible pathogens such as viruses and bacteria while leaving one’s ‘self’’ unharmed. 
The adaptive immune system, composed of B and T lymphocytes, is capable of mounting 
highly effective, antigen specific immune responses against a broad range of different 
antigens. This broad reactive capacity results from rearrangement of genetically encoded 
receptor subunits during T and B cell development, which are linked together using 
a random sequence of nucleotides.28 The addition of random nucleotide insertions creates 
a highly diverse pool of T and B cell receptors, required to combat the many pathogens one 
might encounter. Yet, it also allows for the generation of immune cells with the propensity 
for autoreactivity.  The removal of these potential deleterious immune responses from 
the pool of immune cells during T cell development is enforced in a process referred to as 
induction of central tolerance.29 
T cells undergo an essential part of their development in the thymus, where specialized 
medullary thymic epithelial cells (mTECs) express and present self-antigens under 
the governance of the autoimmune regulator gene AIRE.30 T cells recognizing self-derived 
epitopes on the surface of mTECs commit to apoptosis or become anergic, rendering 
them inert, hereby theoretically clearing the T cell pool of all autoreactive cells. Yet, as 
demonstrated by the existence of various autoimmune diseases, this process of negative 
selection is not flawless. The mechanisms by which potentially autoreactive T cells escape 
thymic education are not clear, but suboptimal antigen presentation due to  low binding-
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affinity of various self-peptides to human leukocyte antigen (HLA)  is implicated. 31,32 
Alternatively, potential autoreactive T cells can express low avidity T cell receptors, causing 
them to survive negative selection despite interacting with self-peptide:HLA complexes on 
the surface of mTECs.33 A third possibility entails the absence of the cognate autoantigen 
from the thymus, either due to differential expression between thymus and peripheral 
tissue or as a result of tissue-specific posttranslational modifications, causing a discrepancy 
between periphery and thymus.34,35 It is conceivable that different mechanisms are 
involved for different autoantigens. Determining the method of tolerance evasion for 
each islet-autoantigen in T1D  will help focus therapeutic interventions as each method of 
tolerance evasion will require its own, tailored treatment approach. Currently, the escape 
of autoreactive T cells from the thymus is viewed as deleterious, yet islet-reactive T cells 
are not exclusive to T1D patients but can be readily detected in the peripheral blood of 
in healthy individuals as well. Therefore, determining the actual consequences of thymic 
escape by  analysing these cells in terms of phenotype and function, may help distinguish 
autoreactive T cells involved in disease propagation from “bystander” autoreactive T cells, 
that pose a distraction in the elucidation of disease etiology . 
To restrain the autoreactive cells that have eluded thymic selection, a second mechanism 
of tolerance exists, known as peripheral tolerance. Regulatory T cells (Tregs), which repress 
rather than promote immune activation upon activation, are pivotal in this process of 
peripheral tolerance. Tregs can be either naturally occurring Tregs, (nTreg), which suppress 
immune responses in a non-antigen-specific manner, or induced suppressor cells (iTregs) 
which act in an antigen-specific manner.  In T1D a diminished functionality of Tregs as 
well as increased resistance of autoreactive effector cells to Treg suppression have been 
reported, contributing to the immune dysregulation required for autoimmune diseases 
to occur 36,37.  The actual mechanism by which autoreactive T cells in T1D increase their 
resistance to regulation by Tregs remains unknown thus far and its elucidation may offer 
opportunities to correct this imbalance and revert aberrant immune responses, or even 
prevent them from ever happening at all. 
Several events have been proposed to precipitate autoimmunity in T1D by creating 
immunological “danger signals” that attract autoreactive cells to the site of the pancreas, 
including viral infections, environmental conditions leading to endoplasmic reticulum 
stress or bacterial transposition from the small intestine. 38-41 Yet, at present the trigger 
for the initiation of β-cell destruction remains unknown. After the initial autoantigen-
presentation to the immune system and subsequent immune activation that lead to β cell 
destruction, islet-reactive T cells with different specificities that the original culprit can be 
activated in a process called epitope spreading.42 In addition, unrelated T cells can get 
activated in a non-antigen specific manner via the process of bystander activation.43,44 
Under normal circumstances both these mechanisms are beneficial as they add to improved 
clearance of pathogens, however they pose a cardinal problem in the elucidation of T1D 
pathogenesis as T1D is often diagnosed long after the initial onset of autoimmunity. 




degree of heterogeneity of disease progression found among T1D patients, which 
suggests that perhaps there is no “single” disease mechanism but rather a multitude of 
disease processes with a common final pathway.45 Theoretically, any abrogation of immune 
regulation, such as impaired expression of immune-regulatory molecules or inadequate 
maintenance of autoreactive immune cells, may eventually lead to loss of tolerance and 
consequently start the cascade of  autoimmunity that leads to T1D.
Current evidence suggests that both CD4+ and CD8+ T cells play a pivotal role in 
the process of β-cell destruction.46 CD4+ T cells recognize extracellular antigens and 
promote local inflammation by releasing cytokines, whereas CD8+ T cells recognize 
peptides of intracellularly synthesized antigens on the surface of their target cells, which they 
subsequently lyse upon engagement. The specific destruction of insulin producing β-cells 
in T1D, sparing adjacent neuroendocrine islet cells such as glucagon-producing α-cells 
and somatostatin-producing δ- cells, implies that β-cell-specific antigens are targeted 
during the autoimmune response of T1D. Reactivity against various islet antigens has been 
described for T1D, yet no single islet autoantigen has unequivocally been identified as 
driving the autoimmune process in type 1 diabetes.45,47 In addition to T cells, members 
of the innate immune system have been implicated in T1D development.48  Dendritic 
cells are crucial in the initial antigen -presentation to autoreactive T cells49, whereas 
macrophages and NK cells act as sources of pro-inflammatory cytokines and chemokines. 
In addition, NK cells can directly interact with β-cells leading to their demise.50-52 Several 
pro-inflammatory cytokines produced by the innate immune system have been implicated 
directly in β-cell death, among which most notably interleukin 1β (IL-1β) and tumor necrosis 
factor alpha (TNF-α).  β-cells appear more sensitive to the apoptotic stimulus provided by 
TNF-α and IL-1B than α- and δ-cells, possibly contributing to the selective loss of insulin 
producing cells. 
The first steps towards the discovery of antigenic targets in T1D were made in 1974 with 
the indirect immunostaining of pancreatic tissue with islet cell antibodies from the serum 
of polyendocrine-disease patients.53 To date, multiple β-cell antigen have been found to 
be autoantibody targets among which (prepro-)insulin, the 65 kDa isoform of glutamic 
acid decarboxylase (GAD65), insulin autoantigen 2 (IA2), carboxypeptidase H, zinc 
transporter 8 (ZnT8), imogen-38 and phogrin.54-60 In addition, several self-antigens have 
been found to be targeted exclusively by T lymphocytes and not antibodies, including 
islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), islet amyloid 
polypeptide ppIAPP and heat shock protein 60 (hsp60).61-63 While pivotal in the initial 
discovery of several autoantigens in T1D, the role of autoantigens in disease propagation 
of T1D remains controversial and presently autoantibodies in T1D are viewed as markers 
of immune activation and disease progression rather than causal agents in destruction of 
β-cells. This view is strengthened by reports of T1D development of  in the setting of B-cell 
deficiency.64 Notwithstanding, anti B-cell therapies have been shown to temporarily delay 
the loss of insulin production in T1D in a small group of patients, indicating that the precise 
role of autoantibodies in the disease process of T1D  remains to be determined.65,66 Despite 
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Figure 1. The current view on islet autoimmunity in Type 1 Diabetes. The pathogenesis of type 1 
diabetes revolves around the presentation of islet antigens to CD4+ T cells by professional antigens 
presenting cells. CD4+ T cells propagate the immune response by activating CD8+ and B cells. Once 
primed, CD8+ T cells become licenced to kill β-cells. NK cells can directly interact with β-cells and 
together with other constituents of the innate immune system act as source of (potentially β cell toxic) 
cytokines and chemokines.  (B.O. Roep, Nature, 2007 [103])
the fact that recent years have provided renewed understanding of key immunological 
players involved in β-cell destruction (Figure 1), the precise reason why tolerance is lost 
against β-cell antigens in type 1 diabetes remains obscure to date.
Genetic contribution to T1D susceptibility 
As described previously, the familial clustering of T1D has long suggests involvement of 
genetic factors in T1D susceptibility. Proof hereof came with the association of the human 
leukocyte antigen (HLA) locus and T1D development.67-69  The HLA complex, or major 
histocompatibility complex (MHC), is a highly polymorphic gene locus containing more 




The most important regions of the MHC for T1D are the HLA class I and II genes that 
encode surface molecules involved in presenting intracellular peptide fragments to T 
lymphocytes, with  the greatest risk modifier for T1D development mapping to the HLA 
class II locus.72 CD8+ cytotoxic T cells recognize their cognate antigen in the context of 
MHC class I, whereas CD4+ T cells recognize antigen in the context of class II molecules. 
Genetic fine mapping has revealed that polymorphic DR and DQ α-β heterodimers, 
encoded by the HLA-DQB1 and HLA-DRB1 genes, are central to disease susceptibility.73 
Due to the high degree of linkage disequilibrium within the HLA locus, certain alleles 
often occur together and are referred to as haplotypes.  Two specific haplotypes carry 
the greatest risk for T1D, i.e. DR3 (DRB1*03:01-DQA1*05:01-DQB1*02:01) and DR4 
(DRB1*04:01-DQA1*03:01-DQB1*03:02).74 Over 90% of all T1D patients express either 
DR3 or DR4, while only 40% of non-affected carry either haplotype.75,76 Separately, DR3 
and DR4 increase susceptibility for T1D (odds ratios of 3.6 and 11.4, respectively), yet 
their risks act synergistically and individuals heterozygous for HLA-DR3/DR4 have up to 
a 47-fold increased risk compared to the general population.72 This extreme risk haplotype 
is present in 2.3% of United States-born Caucasian children, while 39% of patients who 
develop T1D before the age of 20 have this specific genotype.77 Other HLA haplotypes 
increase the risk of type 1 diabetes to a lesser extent, while some haplotypes even seem 
to protect against developing this condition. The DR15-DQ6 (DRB1*15:01- DQA1*01:02- 
DQB1*06:02) haplotype is present in ~20% of the general population but only in 1% of 
T1D patients and has a dominant protective association with T1D with and odds ratio of 
0.03.72,78 Due to a high degree of linkage disequilibrium it has been difficult to determine 
other, weaker, genetic risk factors within the HLA locus. Still, the independent effect of 
several HLA class I genes on T1D susceptibility, most notably HLA-B*57:01 and HLA-B-
39:06, was discovered recently, 79,80.  The mechanism by which HLA alleles influence T1D 
risk is not completely clear, but it is presumed that the risk conferred by these alleles and 
haplotypes relates to specificity of self-peptide binding and presentation.47,81 
In addition to the HLA locus 58 non-HLA regions have been found to associate with 
T1D development.82-85 In contrast to the HLA region, which is thought to account for ~50% 
of all genetic risk in T1D, the majority of these T1D risk loci only carry a moderate risk for 
disease development (OR 1.1~1.5).83,84,86 Among the first non-HLA regions discovered to 
associate with T1D are the INS locus, harboring the gene coding for insulin, and the CTLA4 
locus which codes for the immune-regulatory surface receptor cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4).87,88 Compared to other known non-HLA risk regions, these 
regions carry a relatively large genetic risk which might explain why their associated 
genetic risk for T1D susceptibility was be detected  in relatively small patient studies 
prior to the large cohort genome-wide associated studies (GWAS). The INS locus became 
a premier candidate for genetic association with T1D due to insulin’s central role in glucose 
homeostasis and its unique distinction as the only known β cell-specific antigen. Evidence 
for genetic linkage of the insulin gene with T1D came when variation of a variable number 
of tandem repeats (VNTR) upstream of the INS gene was shown to associate with risk 
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for T1D development.89-91 Alleles with short (class I) VNTR elements predispose to T1D, 
while longer (class III) VNTR alleles  are dominantly protective. The length of the VNTR 
influences expression of the INS gene in cis, with class III alleles causing a 20% reduction 
of insulin expression in the pancreas, but up to threefold higher expression in the thymus 
compared to class I alleles.3,92 It is hypothesized that the increase in thymic insulin 
expression facilitates negative selection of autoreactive cells, thereby diminishing the risk 
for T1D development.92,93 Overall, the role of the INS locus can be viewed as prototypical 
for the role of the thymus in the development of autoimmune diseases, where proper 
education of T-cell is critical in regulating autoimmunity. The discovery that the genetic 
risk of the INS region was linked to thymic expression of the autoantigen prompted further 
investigation and a role for differential thymic expression in the occurrence of autoreactivity 
was postulated for additional islet-autoantigens in T1D, i.e. islet antigen 2 (IA-2) and islet-
specific glucose-6-phosphatase catalytic subunit related protein (IGRP). The latter will be 
discussed in chapter 2 of this thesis.  
The CTLA4 region was the third genetic locus to be associated with T1D predisposition. 
The CTLA4 gene encodes a receptor on the cell surface of T lymphocytes that negatively 
regulates co-stimulation of T cells, by binding the same B7 ligand as the activating  T cell 
receptor CD28.94 In contrast to CD28, the intracellular part of CTLA-4 has phosphatase 
activity that downregulates the intracellular signals that take place after the T-cell 
receptor engages with its cognate HLA:peptide complex and thereby inhibits immune 
activation.  The CTLA4 gene was first shown to be associated with the risk of T1D in 
several  candidate gene study and more recently GWAS have confirmed the association 
of the CTLA4 locus with not only T1D, but also rheumatoid arthritis, celiac disease and 
autoimmune thyroid disease.95-97 The association of CTLA4 polymorphisms with multiple 
autoimmune diseases underlines the importance of its immune regulatory capacities. It is 
conceivable that polymorphisms within the CTLA4 region lead to altered expression or 
functionality of CTLA-4 and thus aberrant immune regulation. Yet, despite fine-mapping 
of the genetic risk to a single nucleotide polymorphism (SNP) located near the 3’ end of 
the CTLA4 gene, to date no actual functional implications have been attributed to this 
polymorphism. The potential of CTLA-4 modulating agents in treatment of autoimmune 
disease has recently been indicated by a clinical trial with abatacept, a CTLA-4 fusion 
immunoglobulin, that showed a temporary delay of β-cell loss in treated recent onset T1D 
patients. Thus, elucidating the  mechanism behind the genetic association of the CTLA4 
region with autoimmune diseases may provide more novel therapeutics and tailored 
treatment strategies .  
 Many of the T1D-associated non-HLA loci have only recently been discovered through 
comprehensive GWA studies  in which large cohorts of T1D patients and matched controls 
are analyzed for over 500,000 different SNPs, covering the whole human genome.83 
The vast majority of the newly identified risk regions has at most a modest impact on 
disease susceptibility, reflected by low odds ratio  (varying from ~1.1 to ~2.0), and many 




harbor genes with immunological functions and  show similarity to the CTLA4 locus as 
they associate with susceptibility for multiple  autoimmune diseases, for the majority of 
associated regions no validated causal gene has been identified. Further, for those loci with 
validated causal genes the mechanisms through which these genetic variations influence 
disease remains unclear. It is estimated that taking all currently known disease-associated 
genetic variation into account approximately 40-88% of the observed familial clustering, 
or heritability, of T1D can be explained.73,98-100 The remaining ’missing heritability’ is 
thought to be caused by genetic variations that are not investigated in GWA studies, 
such as deletions, insertions and copy-number variants in addition to rare genetic variants 
with a frequency too low to properly detect in GWA studies. Additionally gene-gene 
and gene-environment interactions may modulate the risk of genetic variants, and these 
effects cannot be directly investigated with genomic screening.101 Environmental triggers 
may alter gene transcription through epigenetic modifications such as DNA-methylation 
or alterations of the histone code102.  Alternatively, environmental changes can influence 
the expression small non-coding RNAs, e.g. microRNAs, which regulate gene expression 
at a post-transcriptional level.  Identification of the ’missing genetic risk’ and elucidation 
of the pathways by which disease associated genes contribute to disease development 
is crucial for the clarification of T1D pathogenesis. Genetic predisposition undeniably 
contributes to disease occurrence, yet by itself it is not sufficient for disease development 
as demonstrated by the incomplete concordance of affected twin pairs and the discrepancy 
between occurrence of very-high risk genotypes versus disease prevalence. Additional 
immune dysregulation appears to be required to ‘hot-start’ the autoimmune destruction 
of β-cells. Identifying factors that modulate genetic risk through gene-environment 
interactions might reveal potential triggers preceding disease development and may lead 
to new therapeutic modalities and strategies of disease prevention. 
AIMS OF THIS THESIS
Identification of the cellular mechanisms involved in the occurrence and persistence of 
autoreactive lymphocytes is key for understanding T1D etiology. Comparing autoreactive 
T lymphocytes from healthy individuals and T1D patients can provide clues as to what 
the driving force is for the destruction of β-cells and might designate potential targets 
for (immune) intervention. Elucidating in what way T1D associated gene variants actually 
contribute to disease development, i.e. understanding the functional aspects of genetic 
risk, and how genetic control of autoantigens influences autoimmunity may provide crucial 
clues to the clarification of the enigma of T1D. This thesis aims to answer several of these 
issues by investigating the role of transcriptional and post-transcriptional gene control 
in T1D. 
In chapter 2 the immunological implications of differential expression and splicing of 
G6PC2, the gene coding for the islet-autoantigen IGRP, and the role of thymic education 
on the occurrence of IGRP reactive lymphocytes is discussed. In chapter 3 we compare 
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IGRP-reactive T lymphocytes between health and disease and identify a major difference 
in proliferative capacity that associates with differential microRNA-mediated regulation of 
the pro-apoptotic FAS and TRAIL pathways in diabetogenic T lymphocytes. Chapter 4 of 
this thesis discusses the phenotypic effects that rare genetic variants located within known 
T1D risk genes can exert by affecting the post-transcriptional control of microRNAs, while 
chapter 5 provides evidence that the (AT)n microsatellite in the CTLA4  3’UTR is causal for 
the association of the CTLA4 with T1D susceptibility via reduced CTLA-4 expression in 
lymphocytes of individuals carrying susceptibility alleles.
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Thymic expression of self-antigens during T-lymphocyte development is believed to 
be crucial for preventing autoimmunity. It has been suggested that G6PC2, the gene 
encoding islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), is 
differentially spliced between pancreatic beta cells and the thymus. This may contribute 
to incomplete elimination of IGRP-specific T lymphocytes in the thymus, predisposing 
individuals to type 1 diabetes. We tested whether specific splice variation in islets vs 
thymus correlates with loss of tolerance to IGRP in type 1 diabetes. Expression of G6PC2 
splice variants was compared among thymus, purified medullary thymic epithelial cells 
and pancreatic islets by RT-PCR. Differential immunogenicity of IGRP splice variants was 
tested in patients and healthy individuals for autoantibodies and specific cytotoxic T 
lymphocytes using radiobinding assays and HLA class I multimers, respectively. Previously 
reported G6PC2 splice variants, including full-length G6PC2, were confirmed, albeit that 
they occurred in both pancreas and thymus, rather than islets alone. Yet, their expression 
levels were profoundly greater in islets than in thymus. Moreover, three novel G6PC2 
variants were discovered that occur in islets only, leading to protein truncations, frame 
shifts and neo-sequences prone to immunogenicity. However, autoantibodies to novel or 
known IGRP splice variants did not differ between patients and healthy individuals, and 
similar frequencies of IGRP-specific cytotoxic T lymphocytes could be detected in both 
patients with type 1 diabetes and healthy individuals. We propose that post-transcriptional 
variation of tissue-specific self-proteins may affect negative thymic selection, although this 
need not necessarily lead to disease.




Type 1 diabetes is characterised by the autoimmune destruction of insulin-producing 
beta cells in the pancreas. Autoreactive cytotoxic T lymphocytes (CTLs) are pivotal in 
the actual beta cell destruction and type 1 diabetes development. While the majority of 
autoreactive T cells are thought to be deleted during their development in the thymus1, 
the process of thymic education appears inherently incomplete, as islet-reactive T cells can 
be readily detected in peripheral blood of both patients with type 1 diabetes and healthy 
individuals.2-4 Proper negative selection of autoreactive T cells is dependent on 
the presentation of peripheral tissue antigens by medullary thymic epithelial cells (mTECs) 
and thymic dendritic cells under the control of the transcription factor autoimmune 
regulator (AIRE).5,6 T cells recognising self-peptide presented by thymic dendritic cells 
or mTECs with high avidity are removed from the T cell repertoire through apoptosis. 
However, T cells recognising autoantigens with low avidity7,8, or T cells reactive against 
self-epitopes that are not expressed in the thymus, may evade negative selection and 
escape into the periphery.9 
Several islet antigens have been proposed as antigenic targets for autoreactive CTLs 
in type 1 diabetes development, among which is islet-specific glucose-6-phosphatase 
catalytic subunit-related protein (IGRP).10-12 IGRP is a 355-amino acid endoplasmic reticulum-
embedded phosphatase that plays a role in glucose homeostasis.13,14 Increased reactivity 
against IGRP has been observed in patients with recent-onset type 1 diabetes, implying 
involvement of IGRP-reactive T cells in the development of human type 1 diabetes.3,15 
The gene coding for IGRP, G6PC2, can give rise to multiple splice variants, and it has been 
hypothesised that the incomplete tolerance to IGRP is caused by differential expression 
of splice variants between the thymus and pancreatic islets.16 Notably, G6PC2 transcripts 
containing exons 3 and 4, including full-length G6PC2, have been reported to be absent 
from the thymus and suggested to be involved in the incomplete tolerance towards IGRP 
in type 1 diabetes.
Here, we investigated whether differential expression of G6PC2 splice variants 
between the thymus and pancreas indeed contributes to incomplete negative selection 
and increases the risk of disease development.  For this, expression of G6PC2 in purified 
mTECs, whole fetal thymus and pancreatic islet cells was analyzed. Next, we tested for 
humoral immunogenicity of IGRP isoforms in 60 type 1 diabetes patients and 60 matched 
healthy individuals. Finally cellular immunogenicity of G6PC2 splice variants was tested 
in peripheral blood of recent onset type 1 diabetes patients and healthy HLA-matched 
subjects using quatum-dot (Qdot) labeled peptide-MHC (pMHC) multimers.
METHODS
Tissue samples
Purified mTECs were obtained by 24 h incubation of neonatal tissue with dexamethasone. 
Snap-frozen neonatal thymic tissue was obtained from neonates requiring cardiac surgery, 
CHAPTER 2
30
as described.17 Human islets were obtained from the islet isolation core at the Leiden 
University Medical Centre and stored in Trizol upon isolation. After informed consent had 
been given, heparinised blood samples were obtained from type 1 diabetic patients in 
the first year after diagnosis, and all samples were treated identically according to standard 
procedures. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll–Isopaque 
density gradient centrifugation; they were then frozen and kept in liquid nitrogen until use. 
HLA-A2 (HLA-A*0201) typing was confirmed by flow cytometry using FITC-conjugated 
HLA-A2 antibodies (BD Biosciences, Franklin Lakes, NJ, USA). The study was approved by 
the ethics committees of all centres involved.
Detection of splice variant
Cells and tissue samples were lysed using 1  ml Trizol, and total RNA was obtained 
according to the manufacturer’s protocol. Total RNA was treated with DNAse (Qiagen, 
Venlo, the Netherlands) for 45  min at room temperature to remove potential genomic 
DNA carry-over. RNA was subsequently cleaned using RNAeasy columns (Qiagen). First-
strand cDNA synthesis was performed using Superscript III Reverse Transcriptase (Life 
Technologies, Carlsbad, CA, USA) in combination with oligo-dT primers.
RT-PCR amplification was performed using 0.4  μmol/l sense and anti-sense primer, 
0.2 mmol/l dNTPs (Promega, Madison, WI, USA), 1.5 mmol/l MgCl2 (Promega) and 1 U 
GoTaq Flexi DNA polymerase (Promega) in 25  μl reaction volume. Initial denaturation 
was carried out at 95°C for 2 min, followed by 40 cycles of denaturation at 94°C for 30 s, 
annealing at 60°C for 30 s and extension at 72°C for 1 min. Unless stated otherwise, 10 ng 
cDNA template was used per reaction.
Sequencing templates were generated using 1 U Pfx50 DNA Polymerase (Invitrogen, 
Breda, the Netherlands) with an elongation temperature of 68°C. Other conditions 
were identical. The nucleotide sequence of all splice variants found was confirmed by 
polyacrylamide gel sequencing using the Thermo Sequenase Primer Cycle Sequencing kit 
(GE Healthcare, Zeist, the Netherlands) according to the manufacturer’s instructions.
Radiobinding assay
Sera from 60 recent-onset islet antibody-positive type 1 diabetic patients and 60 age- 
and sex-matched controls (mean age 12 years, range 0–34 years; male/female ratio 1.7) 
were obtained. G6PC2 transcripts were subcloned into the pTNT (Promega, Leiden, 
the Netherlands) backbone using XhoI and NotI restriction sites using T4 DNA ligase 
(Promega) overnight at 16°C. Transcripts were translated in the presence of [35S]methionine 
using the TNT in vitro translation system (Promega). Goat anti-human IGRP antibody G-16 
(sc-33472; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used at 1:50 dilution 
as a positive control. Tracer purification and radiobinding assays were performed as 
previously described.18 Results were expressed as % tracer binding. Reference serum from 
a healthy non-diabetic individual was included in each radiobinding assay. Tracer binding 
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was calculated as (cpmsample − cpmreference)/cpmtotal × dilution  factor  for  each  sample. Cold 
target inhibition with unlabelled in vitro translation products leading to loss of signal was 
performed for each target, confirming assay specificity.
Peptides
Peptides were synthesised using solid-phase Fmoc chemistry. All peptides were analysed 
by reverse phase HPLC (purity >85%) and matrix-assisted laser desorption/ionisation-time 
of flight (MALDI-TOF) MS to confirm the expected mass. Peptide binding to HLA-A2 was 
tested as described.19 IC50 values were calculated using nonlinear regression analysis.
Generation of pMHC monomers and Qdot labelling
Generation of pMHC monomers was performed as described previously.20 Briefly, exchange 
reactions were performed by exposing UV-sensitive pMHC monomers (2 μmol/l in PBS) to 
UV light (366 nm UV lamp; Camag, Berlin, Germany) in the presence or absence (negative 
control) of exchange peptide (200 μmol/l) for 60 min. Multimeric pMHC complexes were 
produced by addition of streptavidin-conjugated Qdot-585, -605, -655, -705 and -800 
(Invitrogen) to achieve a 1:20 streptavidin–Qdot/biotinylated-pMHC ratio.
PBMC staining with Qdot-labelled pMHC multimers
PBMC staining was performed as previously described.7 Briefly, PBMCs (2 × 106) were 
stained with 0.1 μg of each specific IGRP multimer in PBS/0.5% BSA for 15 min at 37°C. 
Subsequently, allophycocyanin (APC)-labelled anti-CD8 and FITC-labelled anti-CD14, 
-CD20, -CD4, -CD40 and -CD16 (all from BD Biosciences, Breda, the Netherlands) were 
added for 30 min at 4°C. After a wash, cells were resuspended in PBS/0.5% BSA containing 
7-aminoactinomycin D (7-AAD) (eBioscience, San Diego, CA, USA) to exclude dead cells 
and analysed using an LSRII flow cytometer (BD Biosciences).
RESULTS
Detection of novel G6PC2 splice variants
To test the extent of differential splicing between thymus and pancreas, the expression 
of G6PC2 was assessed in purified mTECs, whole thymic tissue and purified pancreatic 
islet cells by RT-PCR. Primers were designed annealing to exon 1 and exon 5 of G6PC2 
such that all known splice variants could be amplified in a single reaction. In addition, we 
designed a panel of primers annealing to specific exon–exon boundaries to selectively 
amplify specific splice variants, thereby enabling us to distinguish splice variants with 
similar transcript lengths (Supplementary material Table  1).
Using equal amounts of input cDNA, we observed a distinct and consistent splicing 
pattern of G6PC2 in islets, but not in purified mTECs or whole thymus material 
(Figure 1a). Weak expression of G6PC2 was detectable in purified mTECs, suggesting 
that thymic expression was close to the detection limit of our assay. Indeed, when we 
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increased the amount of thymic RNA per RT-PCR, thymic expression of full-length G6PC2 
and all splice variants became detectable (Figure 1b). Yet, in contrast with pancreatic 
islets, G6PC2 levels in thymus were low and displayed inconsistent patterns between 
thymic samples from different donors. Parallel analysis of a single thymic sample yielded 
a stochastic pattern, with different isoforms detectable in separate RT-PCRs, confirming 
that thymic expression of G6PC2 remained near the detection limit of our assay despite 
optimisation of input material. Nevertheless, in every thymic sample, all isoforms could be 
detected, albeit after specific targeting by selective PCR primers in separate analyses (data 
not shown).
In addition to previously reported ‘conventional’ splice variants that use conserved 
exon–exon boundaries, three novel G6PC2 isoforms (variant A, B and C) were identified 
exclusively in islets. Sequencing of these isoforms showed that these variants resulted from 
non-conventional splicing of exon 1 (partial) and exon 5 (partial) (Fig. 2). Expression of 
these three non-conventional isoforms was confirmed using exon-junction-specific primers 
in three separate islet preparations. Furthermore, we confirmed all previously reported 
conventional G6PC2 isoforms and identified two conventional isoforms not previously 
described lacking exon 2 or exon 3 only (Δ2 and Δ3; Supplementary Figure 1). 




















Figure 1. Expression of G6PC2 in thymus and pancreas. (a) G6PC2 expression was analysed by 
RT-PCR in separate purified preparations of mTECs and whole thymus obtained after cardiac 
surgery and pancreatic islets of non-diabetic organ donors. (b) RT-PCR analysis of G6PC2 in thymus 
using 250  ng cDNA template. A 0.5  ng cDNA template of islet preparation No. 2 was analysed 
in parallel for semiquantitative comparison. The housekeeping gene hypoxanthine–guanine 
phosphoribosyltransferase (HPRT) was used as the reference gene 
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Next, quantitative PCR analysis was performed to assess the relative expression of 
each isoform in the same pancreatic islets analysed by RT-PCR (primer sequences are 
specified in Supplementary Table 2). Expression of splice variants differed slightly between 
islet preparations, yet all isoforms could be readily detected (Supplementary Figure 2). 
However, as previously observed, expression of the novel splice variants, A, B and C, was 
low compared with other isoforms. Given that expression in thymus was detectable only 
around the detection limit, we decided against quantitative PCR approaches for thymic 
expression of G6PC2, as these would not add to the data already obtained. To confirm 
the specificity of our assay for the islet-restricted G6PC2, we analysed total RNA of kidney 
and liver, both known to express high levels of the homologous glucose 6-phosphatase 
(G6PC) in parallel. The specificity of the assay was confirmed by the absence of all isoforms 
in both kidney and liver (data not shown).
Detection of splice variant specific IGRP antibodies
To assess humoral immunogenicity of IGRP, the presence of autoantibodies directed against 
full-length IGRP as well as specific splice isoforms was tested in 60 recent-onset type 1 
diabetes patients and 60 sex- and age-matched healthy individuals using a radiobinding 
assay. 35S-labelled forms of full-length IGRP, the splice variant lacking exons 3 and 4 (Δ3/4, 
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Figure 2. Overview of G6PC2 transcripts and putative protein sequences. Exonic sequences of all 
G6PC2 splice isoforms in-frame (grey), in alternative reading frame (black) and truncated (dotted). 
Putative neo-sequences are underlined, and in-frame protein sequences are displayed in regular font. 
Relative expression levels of transcripts indicated on the right: abundant (bold), low (regular) and 
stochastic (in parentheses). aStop codon; bnovel splice variant
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B and C were created through cell-free in vitro translation. In addition to these naturally 
occurring isoforms, an artificial construct coding for G6PC2 exons 3 and 4 was created to 
directly assess the immunogenicity of these exons. In vitro translation of all tested isoforms 
into protein was confirmed using gel electrophoresis (Supplementary Figure 3).
Antibody reactivity was observed for all tested splice variants, but binding of IGRP 
autoantibodies was comparable between type 1 diabetes patients and healthy individuals 
(Figure 3). Mean antibody titres did not differ among the naturally occurring isoforms or 
between natural isoforms and the artificial exon 3–4 construct. Autoantibody reactivity 
against the islet-specific isoforms A, B and C was not significantly increased compared 
with isoforms expressed in thymus, nor did reactivity against these variants discriminate 
type 1 diabetes patients from healthy participants.
Detection of IGRP specific CD8+ T-cells 
G6PC2 can give rise to at least 10 splice isoforms in addition to full-length IGRP 
(Figure 2). All these isoforms may theoretically act as neo-antigens not present in full-length 
IGRP, as they emerge either through novel exon–exon junctions or shifted reading frames 










































































































Figure 3. Antibody reactivity against IGRP isoforms in type 1 diabetic patients and healthy individuals. 
Radiobinding assays were performed for (a) full-length IGRP, (b) variant Δ3/4, (c) exon 3/4, (d) variant A, 
(e) variant B and (f) variant C. Antibody (Ab) binding was determined as the percentage of radioactive 
tracer that immuno-complexed with human serum (see Methods). T1D, type 1 diabetes. Statistical 
analysis was performed using the Mann–Whitney U test. Median values plus interquartile range (IQR) 
are displayed
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amino acid sequences in pancreas, but not thymus, may lead to autoimmune targeting of 
beta cells. To test whether IGRP peptides contribute to cellular autoimmune responses in 
type 1 diabetes, all putative amino acid sequences of IGRP variants were tested in silico 
for high-affinity binding to HLA-A2*0201. We particularly focused on peptides derived 
from exons 3 and 4, those generated by novel exon–exon boundaries, and peptides from 
the islet-specific isoforms variants A, B and C. Peptides derived from exon 1, present in all 
thymic splice isoforms, were included in the search to compare relative immunogenicity 
of splice isoforms present in thymus with those with a presence limited to pancreatic islets 
(Table 1). All peptides with predicted HLA-A2 binding were synthesised, tested for actual 
in vitro binding, and used to generate HLA multimers as previously described.20
PBMCs of HLA-A2-positive type 1 diabetes patients and healthy controls were stained 
with IGRP-specific pMHC multimers in a combinatorial fashion to detect CD8+ T cells 
against multiple epitopes simultaneously in a single sample, increase staining sensitivity, 
and reduce background signal. As a negative control, pHLA multimers were used that 
were UV-exchanged in the absence of rescuing IGRP peptide and Qdot-labelled in 
the same manner as IGRP pHLA multimers. CTLs against a broad range of IGRP peptides 
were observed that were comparable between recent-onset type 1 diabetes patients and 
healthy individuals (Figure 4). Frequencies of CTLs recognising peptides from the proposed 
high-immunogenic exons 3 and 4 (proposed to be lacking in the thymus) were as common 
as those recognising the supposedly less immunogenic exon 1. T cells recognising IGRP 
isoforms exclusive to pancreatic islets (variants B and C) could be detected at the highest 
Table 1. Predicted HLA-A2*0201 binding peptides derived from G6PC2 transcripts.
Peptide Location Sequence in vitro IC50 (nmol/l)
IGRP3-11 Exon 1 FLHRNGVLI 8195
IGRP23-32 Exon 1 YTFLNFMSNV 7251
IGRP62-70 Exon 1 VIGDWLNLI 1175
IGRP116-125 Exon 3 AMGASCVWYV 787
IGRP117-125 Exon 3 MGASCVWYV 1146
IGRP125-134 Exon 3 VMVTAALSHT 33673
IGRP130-138 Exon 3 ALSHTVCGM 5655
IGRP137-145 Exon 3 GMDKFSITL 521
IGRP152-160 Exon 4 FLWSVFWLI 255
IGRP155-164 Exon 4 SVFWLIQISV 3545
IGRP161-169 Exon 4 QISVCISRV 8532
IGRP170-179 Exon 4 FIATHFPHQV 1285
Variant B28-37 Neo-junction exon 1/5 FMSNVEDQPL 480
Variant B37-46 Frameshift exon 5 LSLPVCTWLL 3379
Variant B38-46 Frameshift exon 5 SLPVCTWLL 60
Variant C66-75 Neo-junction exon 1/5 WLNLIFKCWL 39420
Variant C68-76 Neo-junction exon 1/5 NLIFKCWLL 2150
Variant C69-78 Neo-junction exon 1/5 LIFKCWLLPA 1708
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levels, possibly reflecting the absence of these isoforms from the thymus. Yet, their 
frequencies were equally high in type 1 diabetes patients and healthy individuals.
DISCUSSION
The thymus plays a central role in tolerance induction by eliminating T cells reactive 
against peripheral tissue antigens.1,21 Here, we investigated whether differential splicing 
between the thymus and pancreatic islets of G6PC2, coding for the islet autoantigen 
IGRP, associated with IGRP autoantibodies and circulating autoreactive CTLs. Expression 
of G6PC2 in the thymus and pancreatic islets is similar in quality, yet highly distinct in 
quantity. In contrast with previous research16, all conventional splice variants of G6PC2, 
i.e. isoforms using conserved exon–exon boundaries, could be detected in thymic tissues, 
Figure 4. IGRP-specific CD8+ T cells in peripheral blood of type 1 diabetes patients and controls. 
PBMCs of (a) recent-onset type 1 diabetes patients and (b) healthy individuals were screened for 
the presence of CD8+ T cells recognising IGRP peptides. Peptides are depicted per exon from 
which they are derived; variants B and C refer to peptides derived from islet-specific isoforms. No 
significant differences were detected between type 1 diabetes patients and healthy controls using 
Mann–Whitney U tests with Bonferroni correction for multiple testing. Median values are displayed. 
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even though the expression levels were low compared with pancreatic islets. Despite 
differences in expression of G6PC2 between thymus and pancreas, humoral immunity 
against IGRP splice variants was low in both patients with recent-onset type 1 diabetes and 
healthy individuals. Relatively high frequencies of CD8+ T cells recognising various IGRP-
derived peptides could be detected in peripheral blood of both type 1 diabetes patients 
and healthy individuals. Thus, while differential expression of G6PC2 between pancreas 
and thymus can lead to thymic escape of IGRP-reactive T cells, these autoreactive cells are 
not associated with disease by definition.
It has been suggested that G6PC2 is differentially spliced between pancreatic beta 
cells and the thymus16. Here we show that all conventional G6PC2 isoforms occur in 
the thymus, including full-length G6PC2, albeit in very low frequencies. The only isoforms 
showing islet-restricted expression in our study were the neo-sequence variants, A, B and 
C, resulting from alternative splice sites. Since thymic expression of conventional splice 
variants occurred near the limit of detection, we cannot exclude the possibility that variants 
A, B and C exist in the thymus. Intriguingly, these particular fragments were associated 
with the highest rate of islet autoimmunity.
Owing to their putative absence from the thymus, exons 3 and 4 had been proposed 
to be particularly immunogenic in the pathogenesis of type 1 diabetes because of the lack 
of central tolerance. Here we show that, although present at low levels, exons 3 and 4 are 
transcribed in the thymus. Moreover, our findings indicate that this portion of IGRP gives 
rise to low, rather than high, rates of autoimmunity compared with other IGRP sequences, 
either because of expression leakage in the thymus or because this region does not contain 
immunogenic peptide sequences.
In our search for putative IGRP-derived HLA-A2-binding epitopes, we focused on those 
peptides that are likely to be presented in the thymus despite low thymic expression of 
G6PC2, i.e. peptides with predicted medium- and high-affinity binding to HLA-A2. Recently, 
however, it has been demonstrated that high frequencies of CD8 T cells recognising low-
affinity self-peptides are present in the peripheral blood of type 1 diabetes patients.7,22 
Low-affinity peptides are believed to be presented by mTECs at levels insufficient to 
ensure proper deletion of autoreactive T cells.23 Higher expression of tissue antigens in 
peripheral organs, however, may cause low-affinity peptides to be presented at levels 
sufficient for T cells to be activated, resulting in immune targeting of self-tissue under 
conditions of stress or inflammation. As G6PC2 expression is at least 1000-fold higher 
in pancreas than in thymus, low-affinity peptides might reach sufficient levels on the cell 
surface for T cell activation and the subsequent selective destruction of beta cells. Thus, 
although no differential reactivity against IGRP-derived peptides with high HLA-binding 
affinity was observed between type 1 diabetes patients and healthy individuals, reactivity 
against low-affinity IGRP peptides might still distinguish healthy individuals from patients 
with type 1 diabetes. Further, the immunogenicity of IGRP-derived peptides presented in 
the context of type 1 diabetes-associated HLA class I molecules other than HLA-A2, such 
as HLA-A24 or HLA-B39, remains to be determined.
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In addition to central tolerance through thymic education, autoreactive T cells can be 
controlled by other means, such as peripheral tolerance.24 Extrathymic AIRE-expressing 
cells have been demonstrated to induce tolerance in a murine IGRP-driven model of 
autoimmune disease25 and high-affinity IGRP-specific T cells have been shown to be 
actively regulated by regulatory T cells in mice.26 These findings underscore the idea that 
prevention of autoimmunity goes beyond thymic selection.
Since the discovery of IGRP as an islet autoantigen, its role in the pathogenesis of 
type 1 diabetes has been controversial. High levels of IGRP-specific CD8+ T cells could 
be detected in murine models of type 1 diabetes12, yet, in human type 1 diabetes, 
the contribution of IGRP to the autoreactive CD8+ T cell population was modest. More 
recent findings that IGRP knockout mice have delayed onset, but not absence, of islet 
autoimmunity27,28 suggest that the notion of IGRP as the driving antigen in the NOD mouse 
needs revision. The low antibody titres and CD8+ T cell frequencies we have found against 
IGRP and its isoforms, which are non-discriminative between health and disease, suggest 
that IGRP does not play a crucial role in type 1 diabetes onset, and further investigation into 
the relevance of IGRP as an autoantigen in human type 1 diabetes is therefore warranted.
Although we were unable to directly show presentation of IGRP peptides in the thymus 
or pancreas, in vitro translation of G6PC2 isoforms indicates that translation into protein 
indeed takes place. This implies that IGRP splice variants can actually occur in both 
thymus and pancreas. Thymic presentation of IGRP peptides, however, still appears to be 
insufficient for complete thymic deletion of IGRP-reactive cells, as demonstrated by their 
presence in peripheral blood of patients and healthy individuals
In summary, self-reactive T cells can escape thymic selection because of a discrepancy 
in autoantigen expression between the thymus and pancreatic islets. We propose that 
the role of the thymus in deleting IGRP-specific T cells is limited, as autoimmunity against 
IGRP occurs in both type 1 diabetes patients and healthy individuals despite thymic 
expression of all conventional G6PC2 isoforms. We disprove the hypothesis that exons 3 
and 4 of G6PC2 are more immunogenic than other IGRP sequences because of differential 
central and peripheral expression. Furthermore, we conclude that, although self-reactive 
IGRP-specific T cells escape thymic selection, this does not necessarily cause disease.
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Supplementary Table 1. Primer sequences used for detection of G6PC2 expression.
Specificity Direction Sequence
Generic isoform amplification sense  5’-AGAAGGACTACCGAGCTTACTAC-3’
anti- sense  5’-CAGGTCAATGTTGAGCACCC-3’
Variant A sense sense  5’-TGGGTAGCAGTCTGGGCA-3’
Variant B sense sense  5’-GTCCAATGTTGAAGACCAACC-3’
Variant C sense sense  5’-GGTTAAATCTTATATTTAAATGTTGGC-3’
Splice specific exon 1/3 sense  5’-ATCTTATATTTAAATGGAAGTCCATCTGGC-3’ 
Splice specific exon 1/4  sense  5’-CTTATATTTAAATGACTGACCTGG-3’ 
Splice specific exon 1/5  sense  5’-CTTATATTTAAATGGCATGCTGGT-3’
Splice specific exon 2/3  sense  5’-AACAGGTCCAGGAAGTCC-3’ 
Splice specific exon 2/4  sense  5’-GGTCCAGACTGACCTGGTCATT-3’
Splice specific exon 2/5  sense  5’-AACAGGTCCAGGCATGC-3’
Splice specific  common anti-sense 5’-CTACTGACTCTTCTTTCCGCTTTG-3’
Supplementary Table 2. Primer sequences used for quantitation of G6PC2 expression by qPCR.























































































Supplementary Figure 1. Detection of G6PC2 isoforms in pancreatic islets using splice specific 
primers. Intron spanning sense primers were designed to specifically amplify designated G6PC2 














































Supplementary Figure 2. Expression of G6PC2 splice variants in pancreatic islets. Relative expression 
of G6PC2 was assessed by Q-PCR. Splice variant expression levels differed slightly between islet 
samples No.1 (circle), No.2 (square) and No.3 (triangle) yet all variants could be detected. Expression 
of the variant Δ3 and the novel splice variants Variant A, Variant B and Variant C was low compared to 
other isoforms in all three samples. Error bars indicate 95% C.I.
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Supplementary Figure 3. Autoradiography of 35 S-labeled in vitro translation fragments after 



















































3 SURVIVAL OF AUTOREACTIVE T-LYMPHOCYTES BY MICRORNA-MEDIATED REGULATION OF APOPTOSIS THROUGH TRAIL AND FAS IN TYPE 1 DIABETES
V. M. de Jong, A.R. van der Slik, S. Laban, R. van ’t Slot, 
B.P.C. Koeleman, A. Zaldumbide, B.O. Roep




Autoreactive CD8+ T cells recognizing autoantigens expressed by pancreatic islets lead 
to the destruction of insulin-producing beta cells in type 1 diabetes (T1D), but these T 
cells also occur in healthy subjects. We tested the hypothesis that uncontrolled expansion 
of diabetogenic T cells in patients occurs, resulting from failure to activate apoptosis. 
We compared function, transcriptome and epigenetic regulation thereof in relation 
with fate upon repeated exposure to islet-autoantigen of islet autoreactive T cells from 
healthy and type 1 diabetic donors with identical islet epitope specificity and HLA-A2 
restriction. Patient’s T cells proliferated exponentially, whereas those of non-diabetic origin 
succumbed to cell death. Transcriptome analysis revealed reduced expression of TRAIL, 
TRAIL-R2, FAS and FASLG (members of the extrinsic apoptosis pathway) in patient-derived 
compared with healthy donor-derived T cells. This was mirrored by increased expression 
of microRNAs predicted to regulate these particular genes, namely miR-98, miR-23b and 
miR-590-5p. Gene-specific targeting by these microRNAs was confirmed using dual-
luciferase reporter assays. Finally, transfection of these microRNAs into primary T cells 
reduced FAS and TRAIL mRNA underscoring their functional relevance. We propose that 
repression of pro-apoptotic pathways by microRNAs contributes to unrestricted expansion 
of diabetogenic cytotoxic T cells, implicating microRNA-mediated gene silencing in islet 
autoimmunity in T1D.




Type 1 diabetes (T1D) is an autoimmune disease characterized by the loss of insulin producing 
beta cells in the pancreas, leading to impaired glucose homeostasis. Autoreactive cytotoxic 
T lymphocytes are central to T1D development, as they are responsible for the actual 
destruction of beta cells. Yet, the processes controlling their undesirable proliferation upon 
recognition of autoantigens remain poorly understood.1 Apoptosis, as a physiological 
means of cell elimination, has a critical role in maintaining immune homeostasis.2 Several 
disorders, notably lymphoproliferative disorders and autoimmune diseases, have been 
associated with disruptions in the mechanisms controlling lymphocyte apoptosis.3-6 As 
a general principle, failure to appropriately execute apoptosis in immune cells may lead 
to uncontrolled survival and expansion of autoreactive cells and thus autoimmune disease.
Apoptosis in mammalian cells can be initiated through a cell-intrinsic and a cell-extrinsic 
pathway, both leading to the activation of the caspase cascade. The cell-extrinsic pathway 
depends on the activation of death receptors, such as FAS- or TNF-related apoptosis-
inducing ligand (TRAIL) receptors, on the cell surface.7 The cell-intrinsic pathway involves 
activation of pro-apoptotic Bcl-2 family members in response to developmental cues 
and cytotoxic stimuli, such as cytokine deprivation. Which of these two distinct pathways 
initiates apoptosis in T cells is dependent on the activation status of the cells involved. 
Naive T cells predominantly commit to apoptosis via the intrinsic Bcl-2-dependent route, 
whereas apoptosis in activated T cells can be initiated through both the cell-intrinsic and 
cell-extrinsic pathway.8,9
Recently we have shown that beta cell-specific autoreactive CD4+ and CD8+ T cells 
are present at significantly higher frequency in patients with T1D than in healthy control 
subjects.10 Yet, despite this quantitative difference, autoreactivity is not limited to affected 
individuals, as autoreactive T cells are present in the peripheral blood of healthy subjects 
as well.10,11 The presence of autoreactive T cells in unaffected individuals suggests that 
a qualitative distinction, such as the ability of such cells to proliferate and persist upon 
activation, might exist. On this basis, we hypothesized that a defining characteristic 
of autoreactive T cells from T1D patients would be their propensity for unrestricted 
proliferation upon recognition of cognate islet autoantigen. In contrast, autoreactive cells 
from healthy controls would be tightly controlled by intrinsic regulatory mechanisms.
To investigate whether proliferative capacities differ between pathogenic and non-
pathogenic autoreactive T cells, we compared autoreactive T-cell clones isolated from 
a T1D patient and a healthy control subject. These clones recognized the same peptide 
from the putative islet-autoantigen islet-specific glucose-6-phosphatase catalytic subunit-
related protein (IGRP265–273) in the context of HLA-A*02:01 and displayed comparable 
antigen-specific cytotoxicity in vitro. Yet, despite these similarities, the capacity of these 
clones to expand upon antigenic stimulation differed greatly. While T cells derived from 
a T1D patient expanded exponentially, those from a healthy individual could only be 
propagated for a limited number of antigen-specific stimulation cycles. Transcriptome 
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analysis showed differential gene expression of several pro-apoptotic factors between 
health and disease, among which are FAS (CD95), FASLG (CD95L), TNFSF10 (TRAIL) 
and TNFRSF10B (TRAIL-R2). microRNA (miRNA) profiling revealed that several miRNA 
predicted to regulate these apoptotic genes, that is, miR-98, miR-590-5p and miR-23b, 
were simultaneously expressed at higher levels in patient-derived cells. Using dual-
luciferase reporters assays, the targeting of Fas and TRAIL pathways by these miRNAs 
was functionally validated. Furthermore, a reduction of TRAIL and FAS mRNA following 
nucleofection of miR-98 into primary T cells was observed, indicating that miRNAs indeed 
have the propensity to regulate apoptosis through downregulation of cell-surface death 
receptors and their ligands. Thus, this study identifies a disrupted regulation of Fas and 
TRAIL by miRNAs as potential mechanism underlying the unrestricted expansion of 
diabetogenic, autoreactive T cells in autoimmune diabetes.
RESULTS
Autoreactive T lymphocytes from a T1D patient display an increased 
expansion potential
Previously, we described cloning of autoimmune T cells reactive against amino acid 
265–273 of the islet-autoantigen IGRP from peripheral blood of a healthy individual.12 To 
our knowledge, this is the first and only islet autoreactive CD8 T-cell clone ever isolated 
from a healthy donor, putting us in a unique position to compare health with disease. 
Using fluorochrome-conjugated HLA-A2 tetramer sorting, followed by limiting dilution to 
give rise to single-cell clones, two independent autoreactive T-cell clones recognizing this 
same IGRP265–273 epitope were isolated from peripheral blood mononuclear cells (PBMCs) 
of a recent onset T1D patient. All three T-cell clones elicited comparable in vitro antigen-
specific cytolytic capacity and IFN-γ and granzyme B production upon stimulation with 
IGRP265–273 presented in HLA-A*02:01 and killed HLA-matched primary human beta cells, 
even though they expressed distinct T-cell receptors (described in more detail in Unger 
et al.,12 Babad et al.13 and Unger et al.14). Despite their similarities, CD8+ T lymphocytes 
derived from T1D blood demonstrated the capacity to expand indefinitely, whereas 
the healthy donor-derived T cells collapsed after repeated antigen exposure (Figure 1). 
Thus, patient-derived autoreactive CD8 T lymphocytes appeared to have acquired an 
enhanced survival capacity leading to increased proliferation, which might be due to 
a defective apoptosis response to repeated autoantigen exposure.
Reduced expression of apoptotic genes in autoreactive T cells from T1D 
patients 
To determine whether differences in gene expression could explain the enhanced 
proliferative capacity in diabetogenic T cells, a transcriptome analysis was performed. As 
each clone has its own growth rate, total RNA was obtained at the end of their respective 
growth cycle. We focused our analysis on pro- or anti-apoptotic genes with a central role 
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in the intrinsic or extrinsic apoptosis pathway. In addition, members of the caspase family, 
and genes belonging to the anti-apoptotic inhibitor of apoptosis family were investigated.
Reduced expression of several pro-apoptotic factors from the extrinsic apoptosis 
pathway was observed in patient T cells, among which are FAS and FASLG, TNFSF10, 
encoding TRAIL, as well as its receptor TNFRSF10B (TRAIL-R2, DR5) (Figure 2a). Protein 
expression analysis by flow cytometry showed a similarly reduced expression of Fas, 
FasL, TRAIL and TRAIL-R2 in T1D patient versus healthy individual T cells. Among pro-
apoptotic mediators of the intrinsic apoptosis pathway, only the BAX showed reduced 
expression in both patient clones, whereas other genes were not differentially expressed 
between patients and healthy T cells or did not show consistent expression between 
the two patient-derived clones (Supplementary Figure 1). Within the inhibitor of apoptosis 
family, BIRC5 that encodes the pro-survival factor survivin was upregulated in both patient-
derived T-cell clones. Both diabetogenic clones showed reduced expression of the pro-
inflammatory caspases CASP1, CASP4 and CASP5, as well as the pro-apoptotic caspase 
CASP7 compared with healthy individual-derived T cells. Since the Fas/Fas ligand and 
the TRAIL/TRAIL receptor pathways are known major inducers of T-cell apoptosis, we 
decided to focus on the mechanisms underlying the discrepant expression of these two 
major apoptosis pathways between health and disease.




















Figure 1. Autoreactive cytotoxic T lymphocytes isolated from T1D patients exhibit increased 
proliferation rate upon repeated autoantigen exposure. T-cell clone IGRP#7 (black triangle), IGRP#32 
(black circle) and healthy individual-derived clone FSB (gray triangle) show qualitative differences in 
proliferative capacity. Each symbol represents restimulation with cognate antigen IGRP265–273. Each line 
represents a separate passage, showing reproducibility and maintenance of phenotype.
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T1D T cells express high levels of miR-98, -590-5p and -23b 
Recently it has been shown that death receptor-mediated apoptosis can be regulated by 
miRNAs, implicating post-transcriptional control in the process of apoptosis regulation.15 To 
determine whether miRNAs contributed to the dysregulation of apoptosis in diabetogenic 
autoreactive T-cell clones, miRNA expression was determined using microarray analysis 
(Figure 3). Expression profiles differed between patient- and healthy individual-derived 
autoreactive cells, although the limited sample size did not allow for actual clustering and 
statistical testing.
To determine whether any differences in miRNA expression could explain the differences 
found at mRNA level, the 20 miRNAs that showed highest upregulation in both T1D 
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Figure 2. Reduced expression of extrinsic apoptosis pathway factors in diabetogenic cytotoxic T 
lymphocytes. (a) Gene expression analysis represent patient-derived clones IGRP#7 (white bar) and 
IGRP#32 (black bar). Values are represented as fold change versus healthy individual clone FSB. (b) 
Fold change of mean fluorescence intensity (MFI) of patient clones IGRP#7 (white bar) and IGRP#32 
(black bar) versus FSB. (c) Fluorescence-activated cell sorting analysis of TRAIL, TRAIL-R2, FAS and 
FASL on FSB (dark gray), IGRP#7 (blue) and IGRP#32 (purple). Isotype control is displayed in white.
SURVIVAL OF AUTOREACTIVE T-LYMPHOCYTES BY MICRORNA-MEDIATED REGULATION 
53
3
of FAS, FASL, TNFSF10 and TNFRSF10B using the online microRNA.org16 resource. Three 
of these, that is, miR-98, miR-23b and miR-590-5p, were predicted to target FAS, FASL, 
TNFSF10 or TNFRSF10B transcripts and were selected for functional follow up (Table 1). 
miR-23b, miR-98 and miR-590-5p target members of the Fas and TRAIL 
pathway 
To test whether the predicted miRNA-binding sites in apoptotic genes associated with 
islet autoimmunity were indeed functional, HEK293T cells were transfected with reporter 
vectors containing the respective 3′-untranslated region (3′-UTR) of each gene ligated 
downstream of a luciferase cassette. Control vectors harboring up to two nucleotide 
mutations at each predicted miRNA target site were created to confirm specificity of 
miRNA targeting. In the case for TRAIL-R2 targeting by miR-23b, where two predicted 
binding sites were present, a vector was created where both binding sites were mutated 
(wild-type and mutated sequences are depicted in Supplementary table 1). Dual-luciferase 
reporter assays were conducted in the presence of miR-23b, miR-98, miR-590-5p or 
a negative control miRNA. Transfection of all miRNA lead to specific reduction reporter 




































Figure 3. miRNA and mRNA expression in cytotoxic T1D T lymphocytes. Heatmap of miRNA profile 
showing expression of miRNAs in patient T-cell clone #1 (IGRP#7), #2 (IGRP#32) and healthy control 
clone (FSB). Ranking was performed as fold change of patient clones versus healthy control.
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miRNA (Figure 4). Specificity of 3′-UTR targeting was validated by calculating the ratio 
of repression observed in wild-type 3′-UTR constructs over constructs containing miRNA 
target-mutated 3′-UTRs. Thus, these data indicate that miR-590-5p, miR-98 and miR-23b 
directly bind to the 3′-UTR Fas, FasL, TRAIL or TRAIL-R2, respectively, thereby inhibiting 
translation of these pro-apoptotic factors.
Overexpression of miR-98 reduces Fas and TRAIL mRNA expression in 
primary T cells
To assess the ability of miRNA to regulate pro-apoptotic gene expression in lymphocytes, 
primary CMV-reactive CD8+ T cells were nucleofected with miR-23b, miR-98 or miR-590. 
As negative control a C. elegans derived, miRNA was used. Forty-eight hours post 
nucleofection, cells were harvested and mRNA expression of FAS, FASLG TRAIL and 
TRAIL-R2 was analyzed by qPCR. Nucleofection of primary T cells with miR-98 lead to 
a significant reduction of both FAS and TRAIL mRNA compared with control miRNA 
(Figure 5) . In contrast to the reporter assays, FASLG mRNA levels were not significantly 
downregulated upon treatment with miR-98. Nucleofection of miR-23b lead to a reduction 
of both TRAIL-R2 and FAS mRNA, however efficiency of mRNA reduction varied across 
experiments and the overall effect only reached statistical significance for TRAIL-R2. 
Downregulation of TRAIL-R2 mRNA by miR-590-5p was minimal, but comparable to 
previous findings. miR-590-5p treatment did not result in any downregulation of FASLG 
mRNA, in contrast to the results obtained with previous luciferase reporter assays. Overall, 
with exception of FASLG mRNA, effectiveness of miRNA for their respective targets 
showed comparable levels of mRNA inhibition in primary T cells compared with previous 
reporter assay finding.
DISCUSSION
Presence of islet-reactive cytotoxic T lymphocytes is a conditio sine qua non for 
development of T1D. Yet, the mere presence of islet-reactive cells is not sufficient for 
disease development10,11 and this observation appears to be generally true, as autoreactive 
T cells can be routinely detected in blood of healthy subjects.17 Using a unique series of 
diabetogenic T-cell clones, we here provide evidence that autoreactive CD8+ T cells from 
T1D patients differ qualitatively from autoreactive cells of HLA-matched healthy individuals 
Table 1. Predicted miRNA targeting of apoptotic genes
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Figure 4. Targeting of extrinisic pathway apoptosis genes by miRNA. The ability of miR-23b, mir-98 
and miR-590-5p to target the predicted seed region in the 3′-UTR of FAS, FASLG, TRAIL and TRAIL-R2 
was tested with a dual-luciferase reporter constructs containing the wild-type or target site-mutated 
3’-UTRs. Specific inhibition was calculated as decrease in luciferase activity in wild-type 3’-UTR 
compared with target region-mutated 3’-UTR. Each individual experiment was internally normalized 
against an negative control miRNA (C. elegans cel-miR-67). Bars represent mean±s.e.m. Each 



















































































































Figure 5. Repression of extrinisic pathway apoptosis genes by miRNA in primary cytotoxic T 
lymphocytes. For each gene, values were normalized against treatment with negative control miRNA 
cel-miR-67. Relative mRNA expression was calculated versus housekeeping gene OAZ1 for all 




by displaying increased proliferative capacity upon repeated antigen exposure with 
concomitant reduced expression of the pro-apoptotic FAS, FASLG, TRAIL and TRAIL-R2 at 
gene and protein level and increased the expression of miRNAs regulating these factors, 
that is, miR-23b, miR-98 and miR-590-5p.
One of the hallmarks of autoimmune disorders, and T1D in particular, is the acquisition 
of defects in the regulatory circuits that control cell proliferation and immune homeostasis. 
Two well-known pathways involved in immune homeostasis are the Fas/FasL18 and TRAIL/
TRAIL-R pathways,19 however, their role in T1D appears to be two-fold.20,21 On one hand, Fas 
and TRAIL expression by PBMCs is required for control of autoreactive cells,22 whereas on 
the other hand, expression of Fas or TRAIL on PBMCs may facilitate beta-cell lysis through 
increased death receptor:ligand interactions in pancreatic islets.23,24 It is conceivable that 
both mechanisms occur simultaneously during autoimmune disease progression. Yet, 
the immunoregulatory properties of Fas/FasL and TRAIL/TRAIL-R appear to hold greater 
clinical relevance.25 This is demonstrated for Fas by increased resistance to Fas-induced 
apoptosis by PBMC of T1D patients, which would lead to decreased immune regulation and 
thus increased susceptibility to autoimmunity.26 Indeed, a favorable response to treatment 
with high-dose immune suppression followed by autologous hematopoietic stem cell 
transplantation, correlated with an increase of Fas and Fas ligand expression to levels 
seen in healthy individuals.27 Although the role of TRAIL in T1D has not been studied as 
extensively as Fas, interference with TRAIL receptor signaling correlated with aggravation 
of autoimmune disease28 and administration of TRAIL protected against,29 or alleviated 
severity30 of disease in murine models for T1D. These findings suggest that restoration of 
the apoptosis balance by increasing the expression of Fas and TRAIL pathway members 
would be beneficial despite possible negative effects on organ damage.
In this study, we focused on the differential expression of the Fas and TRAIL pathway 
between autoreactive cells from T1D patients and non-affected individuals. Although 
these two pathways are known regulators of T-cell death, it is likely that other factors 
contribute to the increased survival capacity of the T cells observed in this study. Indeed, 
our mRNA profiling experiments point to several other apoptosis regulators that appear 
differently expressed between autoreactive T cells in health versus disease. For instance, 
the pro-apoptotic BAX was expressed at lower levels in patient-derived autoreactive T 
cells, whereas survivin, a negative regulator of both Fas- and BAX-mediated apoptosis,31 
was expressed higher in these cells. Further, several members of the caspase family were 
differentially expressed in patient-derived T cells, among which are the pro-inflammatory 
caspases CASP1, CASP4 and CASP5, as well as pro-apoptotic CASP7. Although 
the individual roles of each of these apoptosis regulators remain to be clarified, these 
collective findings point to overall anti-apoptotic mRNA expression profile in autoreactive 
T cells in T1D.
The autoreactive T cells used in this study present a rare opportunity to compare 
autoreactivity in health and disease. However, as these cells are expanded in vitro 
we cannot exclude culture artifacts from our analyses, despite the reproducibility of 
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the observed phenotypes. Significant effort was undertaken to analyze the transcriptome 
of polyclonal IGRP265-273T cells directly ex vivo, but unfortunately their low frequencies 
in peripheral blood prevented us to do so in a sufficiently robust and reproducible 
manner. Further, the fragile nature of autoreactive T cells derived from healthy individuals 
precluded miRNA overexpression studies, as the procedure of nucleofection resulted in an 
unacceptable rate of cell death. Therefore, a CMV-specific T-cell clone that expressed FAS 
and TRAIL at levels comparable to the healthy individual-derived autoreactive T cells were 
selected to determine the effect of miR-23b, miR-98 and miR-590-5p overexpression in 
primary T lymphocytes.
Recently, miR-98 has been reported to regulate Fas expression, as well as Fas-
mediated apoptosis in a dose-dependent manner in HeLa cells.15 Furthermore, miR-98 was 
implicated as mediator of the anti-inflammatory effects of glucocorticoids by suppressing 
Fas and Fas ligand, among other factors.32 miR-23b was recently shown to mediate 
neuronal apoptosis in hypoxia-induced brain damage33 and overexpression of miR-23b 
lead to reduced apoptosis in lymphoma cells, whereas inhibition of miR-23b increased 
cell death.34 These findings further underscore the general anti-apoptotic potential of 
these particular miRNAs. Thus far, little is known on the role of miR-590-5p in apoptosis 
regulation, although miR-590-5p is implicated in acute myeloid leukemia and cervical 
cancer.35,36 Interestingly, the seed region of miR-590-5p is identical to the seed region 
of miR-21, a miRNA overexpressed in a wide variety of malignancies,37-40 leading to its 
classification as an ‘oncomir’. Overexpression of miR-21 has many consequences, of which 
the increased resistance to apoptosis is predominant. It can be argued that cancer and 
autoimmune disease are on opposite sides of the immunological spectrum. Treatment 
of cancer focuses on activation of adaptive immunity, whereas the therapeutic strategies 
in autoimmunity target immune regulation. Yet, the finding that two independent but 
functionally related miRNAs are overexpressed in both cancer and autoimmune disease, 
with similar phenotypic consequences in both conditions, creates an interesting parallel 
between autoimmunity and neoplastic disease in which the elucidation of miRNA 
expression may provide novel therapeutic targets for both conditions.
miRNAs are known essential negative regulators of gene expression during T-cell 
development and differentiation.41 A striking example of this is given by miR-155, 
a miRNA extensively studied for its role in hematopoiesis and lymphocyte functioning. 
In mice miR-155 deficiency leads to immunodeficiency, likely through dysfunctioning 
dendritic cells, B and T cells. In contrast, increased expression of miR-155 is linked to 
tumor development,42-44 whereas aberrant expression of miR-155 has been observed 
in several autoimmune diseases including rheumatoid arthritis, multiple sclerosis and 
systemic lupus erythematosus.45 The fact that different levels of expression of a single 
miRNA can lead to both immune deficiency, autoimmune disease and cancer indicates 
the potential therapeutic value of understanding the regulatory mechanisms governing 
miRNA expression. Yet, over the past years insight into miRNA biogenesis has revealed 
its complexity and to date the exact transcriptional cues that regulate miRNA expression 
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remain unclear for the majority of miRNAs.27, 28 miRNA gene control involves various 
regulatory mechanisms, among which are transactivation and transrepression by nuclear 
transcription factors. Expression of miRNA can be influenced by extracellular cues and 
shows tissue- and developmental stage-specific expression.46 Expression of miR-23b is 
influenced by extracellular stimuli and inflammatory cues, among which are estrogen, 
TSH, interleukin (IL)-17 and type I interferons.47 miR-590-5p expression appears to be 
affected by IL-3, macrophage colony-stimulating factor and granulocyte-macrophage 
colony-stimulating factor and is under the control of the lysine methyl transferase SEDT1A 
(a regulator of cell cycle progression).35,48 To date, little is known about the molecular 
pathways regulating mir-98 expression, although v-myc avian myelocytomatosis viral 
oncogene homolog is implicated in the regulation of the let-7 family, to which miR-98 
belongs.49  Although there is still much to be learned about the spatiotemporal expression 
of miRNAs, further elucidation of miRNA regulation may aid in identifying a potential 
common event in the etiogenesis of autoreactive T cells.
miRNAs are inherently pleiotropic and potentially target a wide range of mRNAs. 
Therefore, functional validation of in silico predicted target binding is essential and 
the biological relevance of miRNAs for complex biological processes such as apoptosis 
should ideally be tested only in relevant cell types.50 This is underscored by the discrepancy in 
miRNA efficacy observed in our study between dual-luciferase reporters assays and primary 
T cells. Limited availability of autoreactive T cells and technical difficulties manipulating 
these cells, such as low transfection efficacy and low tolerance for manipulation, impair 
functional miRNA studies for the most relevant cell types in autoimmunity. Here we 
used a top-down approach to identify disparities between autoreactive T-cell clones 
from T1D patients and healthy individuals and identified differential expression of two 
canonical extrinsic apoptosis pathways and miRNAs regulating them, leading to increased 
proliferative potential of diabetogenic autoreactive T cells.
Previously, great effort was put into understanding the roles of protein-coding genes in 
T1D. Our finding that miRNAs can reduce the expression of several key apoptotic molecules 
in cytotoxic T lymphocytes implicate them as modifiers of disease susceptibility in T1D. 
Increased expression of miRNAs may act as a biomarker, distinguishing autoreactive T 
cells in patients from those in healthy subjects. Understanding the mechanisms by which 
autoreactive T cells overexpress miRNAs leading to increased survival and proliferation 
upon self-recognition may offer novel targets for therapeutic intervention. 
MATERIALS AND METHODS 
T cell clones 
The procedure for the isolation of healthy controls T-cell clone (FSB) recognizing IGRP 
have been previously reported.12 Patient-derived T-cell clones IGRP#7 and IGRP#32 were 
cloned and characterized, as previously described.14 All T cells were cultured in Iscove’s 
Modified Dulbecco’s Medium with 10% human serum (Sanquin, Leiden, The Netherlands), 
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supplemented with IL-2 and IL-15. Restimulation was performed in the presence of 
irradiated, cognate peptide-loaded JY cells and irradiated, pooled third-party PBMCs. 
All cells used are routinely tested for mycoplasma before freezing. Informed consent was 
obtained for all material used in this study and was approved by the internal review board 
of our institution.
mRNA and miRNA profiling
Total RNA, including the miRNA fraction, was purified from cytotoxic T-cell clone derived 
from T1D patient and healthy donor by the miRNeasy isolation kit (Qiagen, Venlo, 
The Netherlands). Microarray-based miRNA and whole-genome mRNA expression 
profiling analysis were performed using Illumina (San Diego, CA, USA) human miRNA and 
mRNA arrays (Illumina). The miRNA arrays contained ~1200 assay probes corresponding to 
the all annotated human miRNAs (miRBase, version 12, 2008, The Wellcome Trust Sanger 
Institute, Cambridgeshire, UK). Total RNA labeling and hybridization was performed using 
standard conditions according to manufacturer instructions.
Flowcytometry 
For flow cytometry analysis, aliquots of 2 × 105 cells were incubated with a cocktail of 
monoclonal antibodies on ice for 30 min and washed with phosphate-buffered saline 
supplemented with 0.5% bovine serum albumin. Flow cytometric staining was analyzed on 
a fluorescence-activated cell sorting Accuri (Becton Dickinson, Breda, The Netherlands). 
Analyses were performed on Flow Jo 7.6 (Tree Star, Ashland, OR, USA). Antibodies used 
in this study were FITC-conjugated anti-CD95 (clone DX2, eBiosciences, San Diego, CA, 
USA), PE-conjugated anti- CD178 (clone NOK-1, Biolegend, San Diego, CA, USA), PE-
conjugated anti-CD253 (clone RIK-2, Biolegend) and APC-conjugated anti-CD262 (clone 
DJR2-4, Biolegend). PerCP-conjugated anti-CD8 (clone SK1) and corresponding isotype 
controls were purchased from BD Pharmingen (San Diego, CA, USA).
Dual luciferase assays
HEK293T cells were propagated at 37 °C in Dulbecco’s Modified Eagle’s Medium (Life 
Technologies, Bleiswijk, The Netherlands) supplemented with 10% fetal bovine serum, 
100 U ml-1 penicillin and 100 U ml-1 streptomycin. Cells were regularly passed to maintain 
exponential growth.
Prior to transfection, cells were plated at 50% density in 24-well format cell 
culture plates.
Transfection was performed using Lipofectamin 2000 (Life Technologies), 75 μg of 
reporter plasmid, 15 μg of SV40-RenillaLuciferase plasmid and 50 μg of miRNA mimic 
(HMI0408, HMI0982 and HMI0814; Sigma-Aldrich, St Louis, MO, USA) or negative 
control miRNA (MISSION miRNA, Negative Control 2; Sigma-Aldrich, Zwijndrecht, 
The Netherlands). Cells were harvested 48 h post transfection and dual-luciferase activity 
CHAPTER 3
60
was analyzed using Dual-Luciferase Reporter Assay System (Promega, Madison, WI, 
USA) according to manufacturer’s instructions. Experiments were carried out threefold 
in triplicates.
T cell nucleofection
CMV reactive primary T cells were nucleofected using Human T Cell Nucleofector Kit 
(VPA-1002; Lonza, Basel, Switzerland) on the Nucleofector 2 (Lonza). Cells were prepared 
according to manufacturer instructions with 300 μmol of miRNA mimic. Total RNA from 
primary CD8 T cells was isolated using Nucleospin miRNA kit (Machery-Nagel, Düren, 
Germany). cDNA synthesis was carried out using Superscript III (Invitrogen, Bleiswijk, 
The Netherlands) and oligo-dT primers. Detection of human FAS, FASLG, TNFSF10B, 
TNFRSF10 and OAZ1 was performed using SYBR Green PCR Master Mix (Life Technologies) 
StepOnePlus Real-Time PCR System (Life Technologies). Primer sequences are depicted 
in Table 2.
Statistical anlysis
One-way ANOVA tests with correction for multiple testing with Dunnett’s test were carried 
with the statistical package of GraphPad Prism (Graphpad Software, San Diego, CA, USA).





TNFRSF10B (TRAIL-R2) sense 5’-gaagaaagtccttccttacctgaa-3’
antisense 5’-ccaggtcgttgtgagcttc-3’
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Supplementary Figure 1. Microarray expression analysis of members of the intrinsic apoptosis 
pathway, Inhibitors of Apoptosis (IAPs) family, and caspase gene family in diabetogenic cytotoxic 
T lymphocytes. White bars represent patient derived clone IGRP#7, black bars represent patient 
derived clone IGRP#32. Values are represented as fold change versus healthy individual clone FSB.
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Supplementary Table 1. Sequences microRNA binding sites in the 3’ UTR of TRAIL, TRAIL-R2, FAS and 
FASLG. Alterations made to wild-type binding sequences in order to generated  mutated constructs 
are depicted by underscored, capital letters.
Gene microRNA Variant Sequence
TRAIL miR-98 Wild-type gactctacctcat
Mutated gactcGaGctcat
TRAIL-R2 miR-590-5p Wild-type ttttataagctg
Mutated ttttaCCagctg
miR-23b #1 Wild-type agctgaatgtgat
Mutated agctgCaGgtgat
miR-23b #2 Wild-type agttatgtgaat
Mutated agttaACtgaat
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The genetic variation causal for predisposition to type 1 diabetes (T1D) remains unidentified 
for the majority of known T1D risk loci. MicroRNAs function as post-transcriptional gene 
regulators by targeting microRNA-binding sites in the 3′ untranslated regions (UTR) of 
mRNA. Genetic variation within the 3′-UTR of T1D-associated genes may contribute to T1D 
development by altering microRNA-mediated gene regulation. In silico analysis of variable 
sites predicted altered microRNA binding in established T1D loci. Functional implications 
were assessed for variable sites in the 3′-UTR of T1D candidate risk genes CTLA4 and IL10, 
both involved in immune regulation. We confirmed that in these genes 3′-UTR variation 
either disrupted or introduced a microRNA-binding site, affecting the repressive capacity 
of miR-302a* and miR-523, respectively. Our study points to the potential of 3′-UTR 
variation to affect T1D pathogenesis by altering post-transcriptional gene regulation 
by microRNAs.




Type 1 diabetes (T1D) is an autoimmune disease characterized by the selective destruction 
of pancreatic β cells by T cells.1 It is appreciated that both environmental and genetic 
factors contribute to disease predisposition, although the identity of causal factors remains 
elusive. Identification of the causal genetic factors explaining genetic risk for T1D may 
vastly improve prediction, prevention and treatment. Genome-wide association studies, 
assessing millions of single-nucleotide polymorphisms (SNPs) simultaneously in a large 
number of individuals, have greatly increased the power of genetic association studies 
and yielded new insights into the genetic architecture of T1D.2-5 Yet, except for the MHC 
region, INS and PTPN22, the causal genetic variations conferring risk for diabetes, and 
the mechanism on which they act, remains undetermined. Furthermore, the current 
knowledge on genetic disease predisposition leaves a considerable fraction of disease 
heritability unexplained.6 It is not likely that the discovery of new common variants will add 
to the explanation of heritability, but rather it is expected that rare genetic variations will 
improve insight in heritability.7 
Rare SNPs occurring in non-coding regions have the potential to induce phenotypical 
changes by altering regulatory elements such as promoter sequences8 or 3′ untranslated 
regions (UTRs). The latter may influence gene expression levels by interfering with regulation 
by microRNAs, an important mechanism of post-transcriptional gene regulation.9,10 
Recently it has been shown that SNPs frequently alter accessibility of microRNA-binding 
sites, which may account for individual differences in gene expression patterns.11 
We hypothesized that SNPs in 3′-UTRs of T1D-associated candidate risk genes affect 
T1D pathogenesis by modifying microRNA-binding sites and interfering with gene 
regulation. SNPs located in 3′-UTRs of T1D-associated genes were selected through 
dbSNP and T1D Genetics Consortium databases and assessed for their ability to create 
or disrupt microRNA-binding sites using the PolymiRTS database.12 Our data show that 
variation of functionally relevant microRNA-binding elements within the 3′-UTRs of T1D-
associated genes can have consequences for regulation of T1D risk genes. This suggests 
a novel and unexplored mechanism by which rare SNPs can influence disease pathogenesis 
with relevance for translation of genetic risk and possibly intervention.
RESULTS AND DISCUSSION
Genome-wide association studies have identified 56 genomic regions conferring risk for 
T1D development and subsequent fine-mapping proposed candidate disease genes for 
many of the T1D regions.3 For many T1D loci, more than one gene is implicated, resulting 
in a total of 268 candidate disease genes. We investigated whether known genetic 
variation of 3′-UTRs of these T1D risk genes are predicted to alter microRNA binding by 
cross-reference of known 3′-UTR SNPs of T1D risk genes using the PolymiRTS database.12 
Mature microRNAs exert their repressive function embedded in the multiprotein RNA-
induced silencing complex. The structural conformation of targeted mRNA molecules is 
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known to affect the accessibility of microRNA-target sites to the multiprotein RNA-induced 
silencing complex and has been shown to potently influence microRNA functionality.13 
Therefore, we performed accessibility analysis of each microRNA-target site to estimate 
the probability of microRNA-target duplex formation.14 Accessibility of the predicted 
microRNA sites was computed as the difference (ΔΔG) in free energy gained from 
the microRNA-target formation (ΔGDuplex) and the energetic cost of disrupting the secondary 
structure of the target (ΔGOpen). 
Using the PolymiRTS algorithm, we identified 37 different SNPs within 3′-UTR of T1D 
candidate disease genes, that could affect microRNA binding (miRSNPs) (Table 1) and 127 
in additional genes mapping to the T1D risk loci (Supplementary Table 1). The 37 miRSNPs 
in T1D candidate disease genes were predicted to affect 50 microRNA-binding sites, 
of which 28 (56%) involved disruption and 22 (44%) involved introduction of microRNA 
binding. Accessibility analysis of these sites predicted favorable microRNA–mRNA duplex 
formation by 13 (26%) miRSNPs using a minimum ΔΔG value of −7 kcal mol−1 as cutoff. 
The remainder (74%) of the microRNA-binding sites predicted by the PolymiRTS algorithm 
were calculated to have unfavorable binding characteristics, underscoring the need for 
functional validation of microRNA targets sites procured by in silico analysis.
To address the functional impact of polymorphic microRNA sites in T1D risk genes 
we focused on miRSNPs that were predicted to have functional consequences by both 
prediction models. As proof of principle for both disruption or induction of microRNA 
binding we selected miRSNPs in immune-regulatory genes CTLA4 and IL10 for functional 
validation. Both loci have important functions in immune regulation, which is believed to 
be ineffective in controlling loss of tolerance and immune-mediated beta-cell destruction 
in T1D. Reporter constructs containing the full length ancestral 3′-UTR sequences of 
CTLA4 and IL10 were generated and were co-transfected with 50 pmol of miR-302a* 
and miR-523, respectively in HEK293T cells (Figure 1). miR-302a* showed the capacity to 
inhibit mRNA containing the wild-type 3′-UTR CTLA4, whereas the wild-type IL10 3′-UTR 
was not regulated by miR-523. To address the functional impact of polymorphism within 
the microRNA-target sites we generated the allelic counterparts of the CTLA4 and IL10 
3′-UTR by mutating the luciferase reporter constructs at a single-nucleotide position 
within the microRNA-binding site. Transfection of the mutated 3′-UTR constructs with their 
respective microRNAs resulted in reduced inhibition of luciferase activity by miR-302a* 
with the minor allele of the CTLA4 SNP rs13384548. Conversely, increased gene repression 
was observed for the minor allele of IL10 SNP rs6687786. These data demonstrate that, 
indeed, rare genetic polymorphisms in the regulatory sequences of T1D risk genes have 
the propensity to alter protein levels by influencing microRNA-mediated gene repression.
T1D diabetes is marked by a large variability of disease occurrence and progression 
between affected individuals of different ethnicities. As with regular SNPs, the frequency 
of miRSNPs can differ greatly between different ethnic populations, as demonstrated by 
the IL10 miRSNP rs6687786, which is considerably more frequent in individuals of African 
descent than those of Central European descent (6–8% (ref. 15) vs. 1.3% in dbSNP, resp.). 
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As such, miRSNPs may contribute to variation, disease heterogeneity and incidence, 
and effectiveness of immune intervention therapies targeting T1D between different 
ethnic populations.16 
As the phenotypic effects of any miRSNP are ultimately dependent on co-occurrence 
of both the polymorphic microRNA-binding site and the targeting microRNA itself, further 
investigation into the dynamics of microRNA expression are required to assess the impact 
of miRSNPs on disease progression. Our data validate such undertaking by demonstrating 
that low-frequent 3′-UTR SNPs located in T1D risk genes have the capacity to alter gene 


























Figure 1. Functional validation of IL10 and CTLA4 miRSNPs. Effect of miRSNP in luciferase assay 
after co-transfection of microRNA and 3’UTR reporter constructs.  Full length CTLA4 and IL10 
3’UTRs were cloned directly downstream of the firefly luciferase cassette in the pGL3-Control vector 
(Promega, Madison, WI, USA). Minor alleles of both 3’UTR miRSNPs were obtained by site-directed 
PCR mutagenesis of the wild-type plasmids. Primer sequences are displayed in Supplementary Table 
2. Plasmids were sequence verified.
HEK293T cells were maintained in Iscove’s Modified Eagles Medium (IMDM) supplemented with 10% 
fetal calf serum in 5% CO2 atmosphere at 37°C. Cells were transfected at 30-50% confluency in 
24-well format with 150ng of either wild-type or rare variant pGL3 plasmid, 25ng pRL-TK (Promega) 
and 50 pmol of hsa-miR-302a* (Sigma-Aldrich, St. Louis, MO, USA) or hsa-miR-523 (Ambion, Foster 
City, CA, USA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The ratio of firefly luciferase 
to renilla luciferase was obtained for each well using Dual Luciferase Assay (Promega). Inhibition was 
calculated as decrease in firefly to renilla luciferase ratio compared to HEK293T cells transfected with 
negative control microRNA based on C. elegans microRNA cel-miR-67. Bars represent mean ± SEM. 
Each experiment was performed at least three times in duplicate. For statistical analysis a Student’s 
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Supplementary Table 1. miRSNPs in non-candidate risk gene mapping to T1D risk loci.
Genomic region Gene
Minor allele 
frequency (%) SNP miRNA Consequence
11p15.5 IGF2AS n/a rs17886764 miR-125b Disrupt
miR-125a Disrupt
38.8 rs10770125 miR-581 Disrupt
1.1 rs4930042 miR-370 Create
miR-345 Create
miR-378 Disrupt
n/a rs17880764 miR-586 Disrupt
miR-448 Disrupt
12q13.2 RAB5B n/a rs1050198 miR-154 Disrupt
n/a rs12307159 miR-626 Disrupt
miR-224 Create
n/a rs1050200 miR-544 Disrupt
miR-545 Create
n/a rs1050201 miR-370 Create
miR-661 Disrupt
n/a rs1050202 miR-602 Create
miR-506 Disrupt
n/a rs1050203 miR-506 Disrupt
n/a rs1050209 miR-448 Disrupt
n/a rs7350566 miR-30a-3p Create
miR-30e-3p Create
n/a rs1050231 miR-9* Create
MYL6 n/a rs1063598 miR-564 Disrupt
miR-506 Disrupt
0.2 rs4847 miR-598 Create
IL23A n/a rs13378047 miR-661 Disrupt
15q25.1 MORF4L1 n/a rs16970208 miR-532 Create










RASGRF1 1.6 rs4778732 miR-24 Disrupt
22q12.2 AP1B1 5.0 rs6006095 miR-608 Disrupt
miR-654 Disrupt
2.4 rs8140166 miR-130b Create
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Supplementary Table 1. (continued)
Genomic region Gene
Minor allele 




RFPL1 13.1 rs13053624 miR-425-5p Create
NEFH 28.6 rs1061373 miR-661 Create
miR-637 Create
NIPSNAP1 29.7 rs7609 miR-577 Disrupt
n/a rs13054859 miR-26b Disrupt
miR-26a Disrupt
n/a rs459556 miR-153 Disrupt
NF2 n/a rs3180505 miR-512-5p Disrupt
rs1008515 miR-139 Create
29.3 rs2530680 miR-328 Disrupt
miR-504 Create
30.3 rs1034880 miR-411 Create
miR-603 Disrupt
miR-329 Disrupt
n/a rs11537543 miR-573 Disrupt
CABP7 9.2 rs5997508 miR-657 Create
n/a rs9614043 miR-515-5p Disrupt
miR-519e* Disrupt
7.2 rs5752956 miR-617 Create
ZMAT5 1.1 rs6006230 miR-585 Disrupt
MTMR3 32.8 rs41171 miR-542-3p Create
0.9 rs10212055 miR-566 Disrupt




n/a rs4487184 miR-651 Create
LIF 26.0 rs737812 miR-617 Create
0.02 rs11913927 miR-363* Disrupt
0.03 rs12160405 miR-324-3p Disrupt
16p13.13 CIITA 2.4 rs11074940 miR-539 Create
PRM2 n/a rs452495 miR-337 Disrupt
miR-637 Disrupt
LITAF n/a rs13810 miR-7 Create
16q23.1 ZFP1 7.4 rs7199871 miR-512-3p Disrupt
miR-520f Disrupt







Supplementary Table 1. (continued)
Genomic region Gene
Minor allele 















19.3 rs7206003 miR-496 Disrupt
BCAR1 7.1 rs11640206 miR-129 Disrupt
miR-450 Disrupt
19p13.2 ICAM1 25.8 rs281436 miR-373* Create
miR-616 Create
n/a rs923366 miR-326 Create
miR-518c* Create
25.6 rs281437 miR-31 Create
ICAM5 n/a rs2569710 miR-618 Create
n/a rs2735443 miR-205 Create
RAVER1 n/a rs11539686 miR-299-3p Disrupt
14q24.1 ZFP36L1 n/a rs11623420 miR-374 Create
18q22.2 DOK6 n/a rs1790972 miR-365 Create
22q13.1 SSTR3 1.5 rs8141312 miR-632 Create
miR-346 Create
21q22.3 TMPRSS3 27.0 rs13047838 miR-30a-3p Create
miR-30e-3p Create




n/a rs17449010 miR-338 Create
0.4 rs7786554 miR-99a Disrupt
miR-100 Disrupt
miR-99b Disrupt
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Supplementary Table 1. (continued)
Genomic region Gene
Minor allele 
frequency (%) SNP miRNA Consequence
miR-92b Disrupt
HOXA4 3.2 rs4722662 miR-197 Disrupt
3.2 rs4722661 miR-512-5p Disrupt
HOXA5 0.8 rs17472021 miR-512-5p Disrupt
miR-510 Disrupt
HOXA7 0.4 rs17472084 miR-551a Disrupt
miR-551b Disrupt
4.2 rs17500932 miR-187 Create
n/a rs17500918 miR-492 Disrupt
HOXA9 7.0 rs17500987 miR-517* Disrupt
36.2 rs7810502 miR-539 Create
12p13.31 CLEC2D 18.3 rs2401388 miR-181a* Disrupt






0.1 rs11052491 miR-516-3p Disrupt
1q32.1 DYRK3 3.0 rs17014165 miR-518c* Disrupt
3p21.31 FYCO1 12.4 rs2291471 miR-191* Create
5.7 rs1994493 miR-554 Create
9.5 rs1047444 miR-548c Disrupt
miR-548a Create
CXCR6 46.4 rs2234358 miR-532 Disrupt
XCR1 n/a rs7650968 miR-588 Create
miR-339 Disrupt
CCR1 6.0 rs3774630 miR-663 Disrupt
miR-654 Create
TDGF1 6.9 rs3189859 miR-374 Create
Xp22.2 TMSB4X n/a rs11544905 miR-223 Disrupt
19q13.4 CA11 n/a rs7251936 miR-630 Disrupt
FUT2 34.0 rs603985 miR-186 Create













Supplementary Table 1. (continued)
Genomic region Gene
Minor allele 
frequency (%) SNP miRNA Consequence
0.6 rs281376 miR-150 Disrupt
n/a rs28746182 miR-492 Disrupt
32.9 rs2251034 miR-558 Disrupt
0.3 rs28362843 miR-617 Disrupt
n/a rs2638279 miR-637 Create
FUT1 1.8 rs16982283 miR-518c* Disrupt
18.7 rs12611028 miR-517* Disrupt
24.7 rs28682322 miR-373* Create
miR-616* Create
Xq28 DKC1 3.5 rs7878787 miR-339 Disrupt





FUNDC2 n/a rs1048795 miR-193a Disrupt
miR-193b Disrupt
n/a rs5945283 miR-515-5p Create
miR-519e* Create





12q13.3 RBMS2 20.7 rs941209 miR-517b Create
BAZ2A n/a rs11541997 miR-299-3p Disrupt
9.4 rs12296335 miR-485-5p Disrupt
PTGES3 n/a rs28413138 miR-489 Disrupt
STAT6 n/a rs7316645 miR-630 Create
miR-626 Disrupt






R3HDM2 n/a rs7309842 miR-539 Disrupt






DDIT3 n/a rs1054519 miR-224 Disrupt
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Supplementary Table 1. (continued)
Genomic region Gene
Minor allele 
frequency (%) SNP miRNA Consequence
miR-204 Create
miR-211 Create
KIF5A n/a rs12370421 miR-421 Create
B4GALNT1 0.4 rs3741418 miR-635 Disrupt
OS9 n/a rs10403 miR-605 Disrupt
rs1050022 miR-373* Create
miR-616 Create
n/a rs1050038 miR-218 Disrupt
34.1 rs1050045 miR-639 Create
n/a rs1050051 miR-654 Disrupt
MARCH9 25.6 rs1048691 miR-520a* Create
miR-525 Create
21q22.3 PFKL n/a rs1057197 miR-542-3p Disrupt
C21orf2 1.7 rs9306098 miR-339 Create
2q11.2 AFF3 16.0 rs4851212 miR-595 Create
LONRF2 19.5 rs2309822 miR-345 Create
23.3 rs2309821 miR-659 Disrupt
CHST10 3.8 rs10187094 miR-504 Create
n/a rs13419601 miR-491 Create
miR-625 Create
3.8 rs6759686 miR-510 Create
Supplementary Table 2. Primer sequences
Primer Sequence (5’ to 3’)
IL10 3’UTR Cloning F AAAAAAAAAAGCTAGCACAATGAAGATACGAAACTGA
IL10 3’UTR Cloning R AAAAAAAAAAGCTAGCACCAGAACATGATGTGAATAAG
IL10 3’UTR Mutagenesis F TAGCCGGGCATGGTGGCGCGTACCTGTAATCCCAGCTACTT
IL10 3’UTR Mutagenesis R AAGTAGCTGGGATTACAGGTACGCGCCACCATGCCCGGCTA
CTLA4 3’UTR Cloning F AAAAAAAAAAGCTAGCAGCAATTTCAGCCTTATTTTATTC
CTLA4 3’UTR Cloning R AAAAAAAAAAGCTAGCAAACGACCACCACAGATTTTTA
CTLA4 3’UTR Mutagenesis F CTTATATTTACGTATGAGACATTTATAGCCGAAATG
CTLA4 3’UTR Mutagenesis R CATTTCGGCTATAAATGTCTCATACGTAAATATAAG
Gene specific region of the cloning primers was elongated with a NheI restriction site (underlined) and 
a poly-A spacer (italic). Polymorphic site are displayed bold and italic. 
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Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is a protein receptor that 
downregulates the immune system. CTLA4 gene variants associate with various 
autoimmune diseases, including type 1 diabetes. Fine mapping of the genetic risk has 
shown that the genomic region near CTLA4 marked by the single-nucleotide polymorphism 
(SNP) CT60A/G (rs3087243) acts as a susceptibility factor. Yet, the functional basis for 
the increased susceptibility conferred by rs3087243 remains unclear. We demonstrate that 
the length of the dinucleotide (AT)n repeat within the CTLA4 3’ untranslated region (3′UTR) 
strongly associates with the risk of SNP CT60A/G (P<6.5 × 10−72). Genomic (AT)n repeat 
length inversely correlated with CTLA4 messenger RNA (mRNA) and protein levels in islet 
autoreactive T-cell lines. Transfer of a long (AT)n element into T cells lead to a reduction 
of mRNA compared to a short (AT)n element. Thus, this study provides evidence for a role 
of the CTLA4 3′UTR (AT)n repeat in the increased genetic risk for islet autoimmunity 
associated with the CTLA4 locus.




T cells need a co-stimulatory signal in addition to the main antigen-driven signal for full 
activation.1 Naïve autoreactive T cells recognizing their target autoantigen may become 
activated through co-stimulation by CD28 on T cells with CD80 or CD86 on antigen 
presenting cells.2,3 Activated Th1 cells orchestrate a cascade of autoimmune responses 
eventually leading to destruction of self-tissue and autoimmune disease. Cytotoxic 
T-lymphocyte antigen 4 (CTLA4) is an essential negative regulator of adaptive immunity.4 
CTLA4 has been implicated as an effector molecule of regulatory T cells,5 and has recently 
been shown to capture its ligands from opposing cells by process of trans-endocytosis, 
leading to decreased co-stimulation via CD28 and resulting in negative immune regulation.6 
The relevance of CTLA4 signaling in immune regulation of autoimmune diseases was 
recently underscored by a clinical trial using Abatacept (CTLA4-Ig) demonstrating 
temporary preservation of beta-cell function in recent onset type 1 diabetes, although 
decline in beta-cell function occurred parallel to placebo-treated individuals after 6 
months of treatment indicating that in addition to CTLA4 other factors are involved in 
the dysregulated immune response in type 1 diabetes.7
Variations of the CTLA4 gene region are associated with increased susceptibility to 
multiple autoimmune diseases, such as type 1 diabetes, 8 celiac disease9 and rheumatoid 
arthritis.10 Despite the identification of the CT60 single-nucleotide polymorphism (SNP; 
rs3087243) as the principal marker for genetic risk,8 the mechanism through which 
polymorphisms of the CTLA4 locus contribute to autoimmune susceptibility remains 
undetermined.11-13. The CTLA4 risk haplotype that is marked by the ancestral allele of CT60 
has previously been associated with reduced messenger RNA (mRNA) levels of CTLA4 
and its soluble isoform sCTLA-4, presumed to be caused by altered gene transcription 
and splicing.14,15 Alternatively, reduced mRNA expression might result from altered post-
transcriptional control of mRNA stability. Post-transcriptional processing is a regulatory 
mechanism involved in the protein expression of several immune factors, including 
tumor-necrosis factor (TNF) and interleukin-1β (IL-1β), which contain regulatory elements 
in the 3′ untranslated region (3′UTR) of their mRNA affecting RNA stability and rate of 
translation.16,17  Previously, genetic variation located within 3′UTRs of disease-associated 
genes has been shown to affect post-transcriptional control and gene expression, thereby 
potentially affecting disease susceptibility.18,19
We investigated whether post-transcriptional regulation of CTLA4 mRNA and protein 
expression is implicated in autoimmune susceptibility by studying polymorphisms located 
within the 3′UTR of CTLA4. Here we show that a structural variant within the 3′UTR of 
CTLA4, consisting of an (AT)n dinucleotide repeat, is in strong linkage disequilibrium 
with the autoimmune risk marker CT60. Long variants of the (AT)n repeat are associated 
with reduced CTLA4 mRNA levels in islet autoreactive T cells and transfer of a long (AT)n 
element leads to a significant reduction of mRNA in T cells, compared with a short 
(AT)n repeat. Thus, variation of the (AT)n repeat represents an explanation for disease 
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association of the CTLA4 locus and implicates altered post-transcriptional regulation of 
the immunoregulatory CTLA4 as a mechanism contributing to genetic predisposition 
towards autoimmune disease.
RESULTS & DISCUSSION
Since post-transcriptional control of any gene is largely determined by its 3′UTR, we 
tested whether the risk SNP CT60 links with variation in the CTLA4 3′UTR. Length of an 
(AT)n dinucleotide repeat within the 3′UTR of CTLA4 presents a major source of variation. 
To determine whether length variation of the CTLA4 3′UTR (AT)n repeat associated with 
risk for autoimmune disease its correlation with the major risk SNP CT60 was assessed 
in a cohort of 360 type 1 diabetes patients (Table 1). Analysis showed that CT60 status 
and (AT)n length were in strong linkage disequilibrium (D’=1.0, P<6.5 × 10
−72). The most 
common, wild-type, repeat (AT)7 was more frequently observed in individuals carrying 
the CTLA4 neutral allele CT60A, whereas alleles containing longer (AT)n elements were 
uniquely associated with the CT60G risk haplotype (Supplementary Table 1). Individuals 
homozygous for CT60A were exclusively (AT)7 homozygous and CT60G homozygosity was 
strongly related with elongated (AT)variant homozygosity (Supplementary Table 2). Thus, 
long (AT)n elements within the 3′UTR of CTLA4 would directly correlate with increased risk 
for islet autoimmunity.
To assess the functional consequences of (AT)n length variation, (AT)n length was 
compared with CTLA4 mRNA levels in autoimmune T-cell lines from type 1 diabetes patients 
and healthy controls reactive against insulin-secretory granules that we had stored in our 
repository from our studies in the past.20  These T cells contain islet autoreactivities without 
bias to certain islet autoantigens. As these T-cell lines had been derived from a series of 
recent onset type 1 diabetic patients as well as non-diabetic, but age and HLA-matched 
control subjects, we could assess the relationship between mRNA and protein levels in 
subjects with susceptible and non-susceptible CTLA4 associated genetic risk profiles.
The T cells were cultured under IL-2/IL-15 enriched and deprived conditions to mimic 
physiological conditions that affect mRNA stability 21 and thus expression levels. CTLA4 
mRNA levels were significantly lower in T cells with long (AT)n elements in both patients 
and healthy individuals, although the low sample size due to the rare nature of islet 
Table 1.




Association of (AT)n length with CTLA4 risk. SNP CT60A/G was tested in 180 recent-onset type 1 diabetic 
individuals. Short (AT)wt alleles were associated with the neutral CT60A genotype. Elongated (AT)variant alleles were 
exclusively associated with the CT60G risk genotype. 
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autoreactive T-cell lines might pose a possible limitation to this observation (Figure 1a). 
Furthermore, (AT)n length correlated with CTLA4 protein expression levels in a series of 
separately isolated, clonal islet autoreactive T cells with varying (AT)n lengths in a dose-
dependent manner (Figure 1b).  To directly test the effect of (AT)n repeat length on gene 
expression, Jurkat cells were transduced with a green fluorescent protein (GFP) reporter 
vector containing the CTLA4 3′UTR with either a short (AT)7 or long (AT)28 element. T cells 
transduced with an CTLA4 3′UTR containing a long (AT)n element displayed markedly 
reduced levels of GFP mRNA, in line with the results obtained from autoreactive T-cell 
lines and clones (Figure 2). Vector integration was similar between constructs as verified 
by quantitative reverse transcription PCR (qRT-PCR; data not shown).
Next, we assessed whether this difference in mRNA levels associated with (AT)n 
repeat length could be attributed to altered mRNA stability. Jurkat cells were transduced 
with GFP constructs as described above and treated with the transcriptional inhibitor 
actinomycin D. Cells were collected at 2, 4, 6 and 8 h after treatment and mRNA 
expression was measured using quantitative PCR. As observed before, increased reporter 
mRNA levels were observed for the short (AT)7 levels, however, the rate of mRNA decay 


























































Figure 1. Expansion of the CTLA4 (AT)n element correlates with decreased CTLA4 levels in 
T-lymphocytes. (a) qRT-PCR analysis of CTLA4 mRNA in autoreactive T-cell lines cultured in the presence 
and absence of IL-2 and IL-15. Comparisons between subjects homozygous for the wild-type short 
repeat ((AT)wt) versus subjects homozygous or heterozygous for an elongated element ((AT)variant) are 
shown. For statistical analysis a Mann–Whitney U-test was performed. Experiments were performed 
in triplicates. (b) Representative intracellular CTLA4 FACS staining of T-cell clones harboring short 




did not differ between reporter mRNA harboring a short (AT)7 or a long (AT)28 element 
(Supplementary Figure S1). 
Variation of the CTLA4 locus has been implicated in type 1 diabetes, but the genetic 
variant causal for disease association remains elusive.22 We reveal a striking linkage 
disequilibrium between the CTLA4 risk marker CT60 and (AT)n repeat length in the CTLA4 
3′UTR, suggesting involvement of this microsatellite in autoimmune susceptibility. 
CTLA4 (AT)n length affected CTLA4 mRNA and protein levels in islet autoreactive T cells 
carrying the disease-associated CTLA4 allele, leading to a reduction in immune regulation 
in the context of human autoimmune disease. The localization of the (AT)n element in 
the regulatory 3′UTR of CTLA4 implies possible involvement of altered post-transcriptional 
regulation in disease association of the CTLA4 locus.
Several other mechanisms by which the CTLA4 risk allele, marked by CT60G, contributes 
to risk for autoimmune diseases have been proposed, including differential splicing15 and 
altered transcriptional regulation.14 Differential splicing of CTLA4 mRNA as explanation for 
the disease association of the CTLA4 locus remains controversial, and conflicting results 
have been reported.23-25 The role of sCTLA-4 in the pathogenesis of type 1 diabetes 
remains unclear, as circulating sCTLA-4 was only detected in a minority of type 1 diabetes 
patients by novel isoform-specific antibodies.26 Further, no direct functional association of 
promoter polymorphisms and altered CTLA4 transcription have been found, suggesting 
that the CTLA4 risk allele is not functionally related to differences in gene transcription.
Intriguingly, the CTLA4 (AT)n repeat is conserved among primates only. This implies that 
the factors determining genetic risk differ between species despite functional homology 





















Figure 2. (AT)n mediates CTLA4 mRNA expression. Jurkat cells were transduced with a vector containing 
a short ((AT)7) or expanded ((AT)28) element ligated downstream of a GFP cassette. qRT-PCR analysis 
for GFP was performed and normalized for the housekeeping gene OAZ1 in triplicates. Results are 
shown as mean ± S.E.M.
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decreased levels of the ligand-independent isoform of CTLA4 (liCTLA-4),27,28, a CTLA4 
splice variant absent in humans.15,29 This discrepancy of genetic association of CTLA4 
between species precludes functional genetic studies to define mechanisms of disease 
association in preclinical animal models.28
Collectively, we propose that length variation of the (AT)n repeat in the 3′UTR is causal 
for the association of CTLA4 with autoimmune disease. Using type 1 diabetes as prototype 
autoimmune disease associated with CTLA4, we demonstrated that the CTLA4 risk allele 
is functionally related to CTLA4 mRNA expression. We propose that the marker status of 
CT60 is explained by its exceptionally strong linkage disequilibrium with length variation 
of the (AT)n repeat in the CTLA4 3′UTR. Individuals carrying risk alleles will have reduced 
CTLA4 mRNA affecting CTLA4 protein levels and impairing immune regulation. It should 
be noted, however, that multiple genetic variants may act in concert to modulate disease 
susceptibility and we cannot exclude that other genetic factors contribute to the genetic 
risk associated with the CTLA4 locus. Genetic risk associated with the CTLA4 locus for type 
1 diabetes is identical for other autoimmune diseases among which celiac disease and 
rheumatoid arthritis. Although in this study only type 1 diabetes patients were analyzed, 
it is likely that our findings can be extrapolated to these autoimmune diseases as well. 
Our study proposes a novel relationship between genetic susceptibility and variation in 
post-transcriptional gene regulation, contributing to immune abnormalities that may add 
to beta-cell destruction.
MATERIAL AND METHODS
Cells lines and clones
Autoreactive T cells against insulin-secretory granules had been isolated from new-onset 
type 1 diabetes patients (n=10) and healthy HLA and age matched non-diabetic individuals 
(n=8). Procedures and clinical background reported in detail in ref (20). Jurkat cells were 
propagated at 37 °C in RPMI-40 supplemented with 10% fetal bovine serum and 2 mM 
glutamine. Cells were regularly passed to maintain exponential growth.
HLA-A2 restricted T cells reactive against insulin, cytomegalovirus and islet-specific 
glucose-6-phosphatase-related protein were cultured in IMDM supplemented with 10% 
heat-inactivated human serum, 2 mM glutamine, 100 U ml−1 of penicillin, 100 μg ml−1 of 
streptomycin, 20 U ml−1 IL-2 and 5 pg ml−1 IL-15 at 37 °C in a humidified atmosphere with 
5% CO2. (AT)n length was determined by sequencing as 7/7 (glucose-6-phosphatase-
related protein), 7/19 (cytomegalovirus) and 28/28 (insulin). All cells used are routinely 
tested for mycoplasma before freezing. Informed consent was obtained for all material 
used in this study and was approved by the internal review board of our institution.
CTLA4 genotyping
CTLA4 polymorphism (CT60 SNP, rs3087243) analysis was performed on genomic DNA of 
recent onset type 1 diabetes patients (n=180) using the Taqman SNP genotyping assay 
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for PCR as supplied by Applied Biosystems (Nieuwerkerk a/d IJssel, the Netherlands). 
PCR amplification of the (AT)n element in the 3′UTR of CTLA4 was performed in a total 
volume of 25 μl, containing 5–10 ng of genomic DNA, 10 pmol of Cy5-conjugated forward 
primer (5′-CCTTTTATTTCTTAAACAAATGTATGAT-3′) and unlabeled reverse primer 
(5′-CAAAAACATACGTGGCTCTATG-3′) at 55 °C. The fragment size was determined using 
an ABI3730 sequencer. For statistical analysis subjects were divided into two groups: with 
a short CTLA4 3′UTR (AT)n element (seven repeats) or long (AT)n element (8 repeats).
qRT-PCR analysis of T cell lines
Total RNA was extracted from autoreactive T-cell lines and primary CD8 T-cell clones 
using a Nucleospin miRNA kit (Machery-Nagel, Düren, Germany). Complementary DNA 
synthesis was carried out with Superscript III (Invitrogen, Carlsbad, CA, USA) and oligo-dT 
primers (Promega, Madison, WI, USA) according to manufacturer instructions. qRT-PCR 
analysis were performed for CTLA4 (Sense: 5′-TAGCTTTCTCCTCACAGCTGT-3′
Antisense: 5′-TTTTCACATTCTGGCTCTGTT-3′) and GAPDH (Sense: 
5′-TGCACCACCAACTGCTTAGC-3′;Antisense: 5′-GCATGGACTGTGGTCATGAG-3′) 
using an iCycler5 with SYBR-green Super-mix (Bio-Rad, Hercules, CA, USA).
CTLA-4 3’UTR cloning and T cell transduction
The CTLA4 3′UTR was cloned downstream of the GFP cassette in the lentiviral vector 
pRRL-GFP using sense primer 5′-AGCAATTTCAGCCTTATTTT-3′ and antisense 
primer 5′-AAACGACCACCACAGATTTTTA-3′. Human DNA isolates were used as 
template. Constructs and length of (AT)n region were sequence verified. Total RNA 
from Jurkat cells was obtained using RNA-Bee (Tel-Test, Friendswood, USA) according 
to manufacturer’s instructions. Complementary DNA synthesis was performed using 
Superscript III (Invitrogen) and oligo-dT primers (Promega) according to manufacturer 
instructions. Quantitative RT-PCR was performed with SYBR-Green Master Mix (Life 
Technologies, Carlsbad, CA, USA) using the StepOnePlus (Life Technologies) system. 
The following primers were used: GFP (Sense: 5′-GAAGCGCGATCACATGGT-3′, Antisense: 
5′-CCATGCCGAGAGTGATCC-3′), OAZ1 Sense: 5′-GGATCCTCAATAGCCACTGC-3’, 
Antisense: 5’-TACAGCAGTGGAGGGAGAC-3′). Each experiment was performed at least 
three times
Fluorescence-activated cell sorting analysis
Ninety-six-well plates were coated with α-CD3 (eBioscience, San Diego, CA, cat #16-
0037-85) at a 1:1,000 dilution for 4 h at 37 °C. T cells were incubated on coated plates 
overnight at 37 °C in full IMDM medium as described above. Before fluorescence-activated 
cell sorting analysis cells were treated with Golgi-stop (BD Biosciences San Jose, CA, USA; 
cat. #554724) for 2 h. Cells were fixed and permeabilized using Cytofix/Cytoperm Plus (BD 
Biosciences, cat. #555028) according to manufacturer protocol. Staining for CTLA4 was 
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carried out for 30 min on ice using an APC-conjungated α-152 antibody (BD Biosciences, 
cat. #560938) at a 1:10 dilution. IgG2a-APC (BD Biosciences, cat. #552893) was used as 
isotype control.
Stastistical analysis
The non-random association between AT length and CT60 was defined by the delta (D’) 
coefficient and was calculated using the UNPHASED software package.30 As the groups 
analyzed appeared to have different variances an unequal variances Welch t-test was 
performed to analyze CTLA4 mRNA expression in autoreactive T cells lines. A paired 
Student’s t-test was used for comparison of GFP mRNA expression in transduced Jurkat 
cells. All tests were two-sided.
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Supplementary Figure 1. CTLA4 (AT)n does not affect CTLA-4 mRNA decay. Jurkat cells transduced 
with a vector containing an (AT)7 (open circles) or (AT)28 (black circles) element were treated with 
Actinomycin D and GFP mRNA was analysed at different time points. Cells were harvested at different 
time points and qRT-PCR analysis for GFP was performed at and normalized for the housekeeping 
gene OAZ1 in triplicates. Results are shown as mean ± S.E.M.
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Supplementary Table 2. Association of (AT)n length with CTLA4 CT60A/G genotype
CT60 / (AT)n wt/wt wt/variant variant/variant
AA 30 0 0
AG 6 92 0
GG 0 4 58
wt= (AT)7. variant = any (AT)n >(AT)7
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GENERAL DISCUSSION AND SUMMARY
Type 1 diabetes is an autoimmune disease that results in the loss of insulin-producing beta 
cells in the pancreas. The etiology of the disease remains incompletely understood, but 
both environmental and genetic factors contribute to disease susceptibility. Elucidating 
the genetic mechanisms involved in disease development will contribute to personalized 
medicine and is invaluable for the development of novel therapies and a potential cure. 
Transcriptional regulation of the islet-autoantigen IGRP is similar between 
pancreas and thymus and not implicated in the loss of tolerance for IGRP 
in T1D
In chapter 2 of this thesis I describe the role of differential splicing of G6PC2 between 
pancreas and thymus in the development of islet autoreactivity. G6PC2 encodes 
the autoantigen islet-specific glucose-6-phosphatase catalytic subunit-related protein 
(IGRP), a known target of autoreactive CD8 T cell in T1D. Previously, Pugliese et al. 
suggested that absence of G6PC2 isoforms containing exon 3 and 4 in the thymus 
contributes to IGRP autoreactivity.1 The thymus plays a key role during T cell development 
as the anatomical site where lymphoid progenitors differentiate and are educated.2 
Through both positive and negative selection a T cell repertoire is formed that can properly 
interact with antigen presenting cells while avoiding immune responses to the body’s own 
tissue.  Potentially autoreactive cells are eliminated in the thymus in a process referred to 
as central tolerance, which involves presenting tissue-specific autoantigens to developing 
T cells and the removal of those cells with the potential to react to these autoantigens. 
That negative selection contributes to the prevention T1D is illustrated by the fact that 
disease promoting INS variant associate with a quantitative reduction of thymic insulin 
expression, which is thought to impair negative selection of INS reactive T cells and promote 
islet autoreactivity.3,4
In 2006 differential splicing of G6PC2 between thymus and pancreas was hypothesized 
to exert an effect on islet-reactivity through incomplete negative selection of IGRP-specific 
T lymphocytes. We initially set out to quantify the autoreactivity against G6PC2 isoforms 
containing exon 3 and 4 in T1D patients,  as these isoforms were supposedly lacking from 
the thymus. However, using G6PC2 isoform specific primers demonstrated that actually 
all G6PC2 isoform that employ conventional splice sites are expressed in the thymus, be 
it at considerably lower levels than in pancreatic islets.  Yet, we did identify three novel 
splice variants that were only detectable in islet-isolates. As thymic expression of regular 
G6PC2 isoforms was already near the lower detection limit of our assays, our inability to 
detect these in thymic tissue might have resulted from technical limitations, rather than 
from actual differential expression between pancreas and thymus. Further, these novel 
islet-specific isoforms employ unconventional splice sites and whether they actually are 
valid isoforms or erroneous byproducts of normal splicing remains to be determined by 
proteomic studies and immunohistochemistry. Yet, if proven to be translated into protein 
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product these isoforms would be an interesting subject for further functional studies, given 
their exclusivity to islet cells.  
Next, we investigated autoreactivity against IGRP isoforms by quantifying IGRP 
autoantibody levels and frequencies of IGRP-specific, HLA-A2 restricted CD8 T cells in 
peripheral blood of patients and healthy individuals. Interestingly, T cells reactive against 
IGRP-derived peptides could be readily detected in the peripheral blood of healthy 
individuals, suggesting that negative selection of IGRP reactive T lymphocytes is incomplete. 
Yet, no significant difference could be detected between T1D patients and healthy 
individuals, implying that the apparent defective negative selection of IGRP-reactive T cells 
is insufficient development of T1D.  In our study we focused on the interaction between 
IGRP and HLA-A2, the class I molecule that occurs with the highest frequencies  among 
T1D patients.5 Ideally we would have also been able to analyze T cells recognizing IGRP 
peptides in the context of other T1D associated HLA molecules, especially HLA-DR and 
HLA-DQ molecules given their strong genetic linkage to T1D development. Unfortunately, 
our technical platform currently precludes us from employing any HLA molecule other 
than HLA-A2.  While it is technically possible to produce HLA class II tetramers, in vitro 
generated HLA-class II monomers are highly unstable.  Their stability can be improved by 
covalently linking the peptide of interest to the HLA class II monomer, yet this increases 
the complexity of their production process and prohibits the  high throughput analysis as 
we have performed here.6,7 If technological advances would allow a similar approach for 
class II HLA molecules as we have performed here for HLA-A2,  it would be interesting 
to determine the immunogenicity of  IGRP splice variants in the context of the remaining 
HLA class I and class II molecules to determine their actual impact on the autoimmune 
response in T1D. 
The presence of IGRP-specific T cells in peripheral blood of healthy individuals 
suggests that incomplete negative selection alone is insufficient for autoimmune disease 
to develop. IGRP reactive T cells can display potent cytotoxic activity in vitro and in vivo.8,9 
Therefore, the protection from β-cells lysis in healthy individuals must be effectuated by 
means other than thymic selection. Potential mechanism involve peripheral suppression of 
autoreactivity by regulatory T cells (Tregs) or inhibitory mechanisms inherent to autoreactive 
cells, e.g. increased activation threshold preventing autoreactive T cells from becoming 
activated,  or activation induced cell death (AICD) causing apoptosis upon recognition of 
an autoantigen.10,11 The role of the thymus in self-tolerance induction of CD4 T cells was 
recently shown to be dependent on the autoantigen involved.12 Although our study was 
not designed to answer this question, it appears that distinct methods of self-tolerance 
induction exist for CD8 T lymphocytes as well and the role of the thymus in the prevention 
autoreactivity against IGRP is limited.
Since its discovery as an islet-autoantigen IGRP has been regarded as one of the driving 
antigens for disease development and progression in mice.13-15 However, its exact role 
in the pathophysiology of human T1D remained controversial as the frequency of IGRP-
specific CD8 T cells in the peripheral blood of T1D patients is modest compared that 
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to murine models.16,17 In our study antibody titers and CD8+ T cell frequencies against 
IGRP and its isoforms were low and non-discriminating between health and disease. This 
suggests against the role of disease-driving antigen for IGRP in human T1D. Still, previous 
studies from our laboratory showed that IGRP-specific CD8 cells are present in human 
insulitic lesions and adoptive transfer of human IGRP-specific CD8 T cells into HLA-A2 
transgenic mice provokes insulitis and β-cell destruction.8,18 Thus, while IGRP does not 
appear to be a driving autoantigen in human autoimmune diabetes, IGRP autoreactivity 
seems to contribute to the etiology of T1D and clarifying its exact role it would 
be worthwhile. 
Concluding, the difference of G6PC2 expression between pancreas and thymus is 
not so much quantitative as it is quantitative. Further, it appears the role of the thymus 
in tolerance induction against IGRP is limited at most and the effect of reduced thymic 
G6PC2 expression on the occurrence of autoimmune disease appears negligible. 
Posttranscriptional control of pro-apoptotic genes by miRNA contributes 
to apoptosis resistance in autoreactive T cells in T1D
In T1D autoreactive CD8+ T-cells destroy insulin-producing β-cells that display their 
cognate autoantigen on the cell surface. Yet, as described in chapter 2 islet-reactive 
T-cells can be readily detected in the peripheral blood of healthy individuals. A potential 
difference between health and disease may be the capacity of peripheral regulatory T 
cells to dampen autoimmune responses or prevent them from even happening.Reduced 
Treg activity has been described for several autoimmune diseases, including T1D.19and, 
increased resistance for regulation by autoreactive T effector cells has been suggested 
as well.20 In chapter 3 of this thesis we compared two autoreactive T cell clones isolated 
from a T1D patient with a T cell clone isolated from a healthy individual, all recognizing 
the same peptide:HLA complex and displaying comparable in vitro cytotoxicity. We 
observed that the healthy individual’s autoreactive T cells could be stimulated for a finite 
number of times before collapsing, a characteristic not observed in autoreactive T cells 
obtained from a T1D patient. Therefore, we tested the hypothesis that in T1D uncontrolled 
expansion of diabetogenic T cells occurs as a result of failure to activate apoptosis upon 
repeated antigen exposure. 
Transcriptome analysis of the T cells clones revealed reduced expression of TRAIL, 
TRAIL-R2, FAS and FASLG, members of the extrinsic apoptosis pathway, in patient-derived 
compared to healthy-donor-derived T cells. This was mirrored by increased expression 
of microRNAs (miRNAs) predicted to regulate these particular genes, namely miR-98, 
miR-23b and miR-590-5p. Gene specific targeting by these microRNAs was confirmed 
using dual-luciferase reporter assays. Finally, transfection of these microRNAs into primary 
T-cells reduced FAS and TRAIL mRNA expression, underscoring the functional relevance 
of these microRNAs in effectuating resistance to apoptosis of autoreactive T cells. Thus, 
we showed that the differences in proliferative capacity between autoreactive T cells 
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from health and disease associates with altered in expression of pro-apoptotic genes and 
the post-transcriptional factors regulating them.
To definitively prove that the increased proliferative capacity of autoreactive T 
cells from T1D patients stems from altered expression of pro-apoptotic factors and 
the microRNAs governing them, we set out to reverse the observed phenotypes via 
molecular intervention. Primary T lymphocytes are notoriously difficult to transfect, but 
we show that nucleofection is a viable way of introducing miRNA into primary autoreactive 
T cells.  Unfortunately, employing this method on T-cells derived from non-diabetic donors 
caused cell death in the majority of cells within 24 hours after treatment. This timeframe fell 
short of the minimal time needed to observe an effect of miRNA treatment, as a resting/
recovery phase for the cells and the time required for the miRNA to assert its effect needs 
to be taken into account. Another difficulty with our initial approach was that the estimated 
half-life for miRNAs is approximately 5 days.21 The proliferative capacity of a T cell clone 
can only be reliably tested at the end of its respective restimulation cycle, which is around 
10 days  for the autoreactive T cell clones described here. To deal with these limitations, 
we opted to use virus-specific T cells that express high levels of FAS and TRAIL and are 
relatively resistant to the negative effects of nucleofection and measure the effect of our 
treatment with quantitative PCR analysis of FAS and TRAIL mRNA. By doing so we were 
able to provide evidence that overexpression of miR-23b, miR-98 and miR-590-5p indeed 
leads to reduced expression of members of the FAS and TRAIL pathways and thereby may 
contribute to increased survival of autoreactive T cells.
Our observations and transcriptome comparisons in this study involved a single 
IGRP265-273-reactive T cell clone derived from a healthy individual and two IGRP265-273-reactive 
T cell clones from a T1D patient. Autoreactive CD8+ T cell clones are extremely difficult to 
produce and maintain in culture without loss of antigen specificity, especially autoreactive 
T cells derived from healthy individuals. The clones used in this study represent the majority 
of IGRP-specific CD8 T cell clones available worldwide, and although the limited number 
of samples poses a potential sampling bias, here we have been able to reproducibly 
investigate the transcriptomes of autoreactive cells that were actually primed in vivo, 
and thus likely involved in β-cell destruction, with their non-pathogenic counterparts 
from healthy individuals. Naturally our study would have been strengthened if more 
clones could have been examined, particularly from the healthy individuals.  We have 
aimed to obtain and compare IGRP specific cells directly after isolation from the blood 
of T1D patients and healthy individuals using a FACS-based approach in an attempt to 
increase the number of T cell clones for our study. Due to the low numbers of circulating 
autoreactive cells of a given specificity in both T1D patients and healthy individuals, using 
this approach we were unable to robustly test mRNA and miRNA expression in T cells 
with a single specificity using this approach. Yet, by comparing pooled autoreactive cells 
with varying specificities from recent onset T1D patients to pooled virus-reactive cells 
from the same individuals we were able to show a significant difference in FAS and TRAIL 
expression between autoreactive T cells and virus-specific T cells within a single individual, 
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which lends support to the notion that autoreactive T cells have impaired expression of 
surface death receptors and a subsequent increased resistance to apoptosis induction 
(unpublished data). Further, given the promising results from these preliminary data I am 
convinced that this approach stands to be an excellent alternative to the laborious cell-
culture and may offer new opportunities to analyse autoreactive T cells directly ex-vivo in 
the near future. 
Thus, repression of pro-apoptotic pathways by miRNAs contributes to unrestricted 
expansion of diabetogenic cytotoxic T-cells, implicating miRNA-mediated gene silencing 
in islet autoimmunity in T1D. Further analysis of the miRNA transcriptome of autoreactive 
cells might provide novel therapeutic options and elucidation of the mechanisms that 
govern miRNA expression may result in the identification of (environmental) triggers 
involved in T1D development. 
Rare variants alter post-transciptional regulation of T1D risk genes
In chapter 4 of this thesis we investigated the possible interaction between rare 
genetic variants and functionality of miRNAs, which play an important role in the post-
transcriptional regulation of gene expression.  Genome wide association studies (GWAs) 
have greatly increased our knowledge on disease-associated genomic regions. However, 
even when taking all verified disease-associated gene variations into account we still 
cannot completely explain the heritability of T1D. GWAs are designed for the detection 
of common single nucleotide polymorphisms (SNPs).  Rare SNPs and structural variations 
such as insertions, deletions and repeats are not analyzed with current GWAs and it is 
therefore hypothesized that the ’missing heritability’ of complex diseases such as T1D  can 
be explained by these types of genetic variations.  
The magnitude of the missing heritability of T1D is subject to debate, with estimates 
for the unexplained heritability ranging from 0% to 40%.22-25 Regardless of the size of 
the unexplained heritability, consensus is that common genetic risk variants are unlikely 
further our understanding  and that future research should focus on structural and 
rare variants.26
In our proof-of-concept study we have investigated rare polymorphisms in T1D risk 
genes with the propensity to influence post-transcriptional gene control by affecting 
miRNA function. miRNAs in general are pleiotropic, with each miRNA regulating up to 
several hundreds of protein-coding mRNAs. In our study we limited our investigation to 
genes with known association for T1D susceptibility and investigated whether they were 
predicted to be under regulatory control by miRNAs. Using in silico modeling we identified 
miRNAs that could potentially interact with mRNA of T1D genes. With gene-targeting 
models we validated these predictions and demonstrated in vitro that rare SNPs, miRSNPs, 
have the capacity to modulate post-transcriptional gene control by instilling or abrogating 
miRNA-mediated gene silencing, a novel mechanism through which rare polymorphisms 
can affect T1D associated gene pathways. Although this study is a proof-of-concept rather 
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than a comprehensive analysis, we already describe several functionally active miRSNPs 
in T1D associated gene loci. Currently little is known about the biological importance 
of the miRNA identified in this study, i.e. miR-302a* and miR-523, and the expression 
patterns of these miRNA.  However, knowledge on both miRNA species and genetic 
polymorphisms is rapidly increasing  and the association between environemtal cues 
and miRNA expression is becoming more clear.27 Although further research is required to 
establish the actual impact of miRSNPs on development and heritability of autoimmune 
diseases, this study provides a potential mechanism by which  environmental factors can 
interact with genetic susceptibility factors in the development of T1D. 
The CTLA 3’ UTR (AT)n microsatellite is causal for the  association of  
the CTLA4 locus with genetic susceptibility for T1D 
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a surface molecule present on activated 
T cells that inhibits the T cell receptor signalling upon binding to its ligands CD80 
and CD86.  It has been hypothesized that inherited variations in the CTLA4 gene can 
increase T cell autoreactivity and thereby play a role in autoimmune diseases such as 
T1D. Indeed, the CTLA4 locus was among the first genomic regions to be associated 
with susceptibility for T1D. Yet, the genetic variant causal for the actual association, as 
well as the molecular mechanisms associated with increased disease susceptibility have 
long remained unknown. Recent fine mapping studies have shown that the region marked 
by the single-nucleotide polymorphism CT60 (rs3087243) downstream of the CTLA4 
3’UTR acts as a susceptibility factor.28,29 This CT60 polymorphism maps to a non-coding 
region and the mechanisms through which it would influence CTLA4 expression remains 
elusive. In chapter 5 of this thesis we provide evidence that a structural genomic variant, 
i.e. the (AT)n microsatellite located within the 3’ untranslated region (UTR) of CTLA4, is 
causal for the genetic association of CTLA4 with T1D susceptibility. First, we investigated 
the association of the CTLA4 (AT)n microsatellite with the T1D risk marker CT60 . Analysis 
showed that CT60 status and (AT)n length were in extremely strong linkage and that CTLA4 
alleles containing longer (AT)n elements are uniquely associated the CT60G risk haplotype. 
Conversely, the protective CT60A haplotype was observed  more frequently in association 
with wild-type, short, (AT)n elements. Thus, long (AT)n elements within the 3’UTR of CTLA4 
would directly correlate with increased risk for islet autoimmunity. In autoreactive T cell 
lines increased microsatellite length associated with a significant decrease in CTLA4 mRNA 
expression and direct transfer of a long (AT)n microsatellite resulted in decreased reporter 
mRNA expression compared to the transfer of a short (AT)n element.
It should be noted that the number of T cell lines studied we have studied here, i.e. 
10 patient T cell lines and 8 control lines, is low and represents a potential limitation to 
our findings. Yet, it should also be appreciated that the cell lines used here are extremely 
rare and generation of additional cell-lines is technically highly demanding. Furthermore, 
the fact that a significant difference between the lines when stratified on (AT)n  genotype 
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was still detected, despite the heterogeneous composition of the cell lines, indicates 
robustness of the association between (AT)n  genotype and CTLA-4 expression. 
In order to assess the effect of the (AT)n  length on CTLA4 expression we transferred 
the 3’UTR of CTLA4 variants with different (AT)n  lengths into a GFP reporter constructs. 
Sequencing analysis excluded any variation other than the (AT)n  element between 
the generated constructs.  Upon transduction of the constructs into a immortalized 
lymphocyte cell line we observed a significant difference on steady state GFP mRNA levels, 
with the construct containing a long  (AT)n  element showing decreased levels of reporter 
mRNA. The use of a long-standing immortalized cell line instead of actual T lymphocytes 
introduces the possibility of culture artefacts or aberrant outcomes due to differences 
in intracellular mechanisms, with the addition of  potential genomic instability due to 
the process of transduction. Yet, as our results were consistent over two separate rounds 
of transduction, performed with separately produced virus batches, we are confident 
these confounders were kept to a minimum and our results reflect the actual influence of 
the (AT)n  repeat on gene expression.
The location of the microsatellite in the 3’ UTR, known for its role in post-transcriptional 
gene regulation, suggests that the mechanisms underlying the observed differences in 
mRNA expression involve altered post-transcriptional control. In our study we did not 
observe any significant effect of the (AT)n  repeat on mRNA decay rate.  While this suggests 
that the (AT)n  repeat does not affect mRNA stability it remains possible that transcription-
dependent factors have acted as rate-limiting factors in our experiment. Proteins with 
a very short half-life, or a RNA-silencing moieties that are consumed as a result of 
their actions would  be equally affected by the actinomycin D treatment used to block 
the transcription of our GFP reporter. The actinomycin D treatment may thereby have 
obscured any mRNA decline that would have normally occurred in vivo between short and 
long (AT)n containing  mRNA. Alternatively, the difference in mRNA levels may be the result 
of different transcriptional regulation, and not altered post-transcriptional control. It is 
known that the location of a genomic element does not necessarily correspond with its 
function and that genomic interactions can occur between regions that are up to hundreds 
of kilobases apart.30 Therefore, while its localization suggests that the (AT)n  microsattelite 
affects post-transcriptional regulation, possibly via  short-lived regulatory molecules, 
our current data do not allow us to exclude long-range gene interactions or differential 
binding of chromosomal moieties as factors in the observed difference in CTLA4 mRNA 
expression. Still, the extremely strong association between the CT60 risk variant and long 
(AT)n  alleles, combined with the direct effect of the (AT)n  repeat on mRNA expression 
suggests a causal role for the (AT)n  microsatellite in the genetic association of the CTLA4 




The last two decades have provided (bio)medical scientists with a wealth of information on 
the genetics of complex diseases such as T1D. Understanding exactly how gene variants 
influence disease susceptibility and determining the interplay between environment, 
genetics and immunology have proven to be the next hurdles to overcome. Achieving 
this goal may enable us to predict disease progression, design novel treatment methods 
and improve patients categorization in order to provide actual personalized medicine. 
The contributions of this thesis are summarized in Figure 1. In short, we reposition 
the proposed alternative splicing of G6PC2 between thymus and pancreas, discuss 
the role of the thymus in tolerance towards the putative islet-autoantigen IGRP and argue 
the validity of  IGRP as an critical islet-antigen in T1D. Further we show that a structural 
genetic variant located with the 3’ UTR of CTLA4 associates with risk for T1D development 
and influences expression of the immune regulator CTLA-4. In addition, we show that 
rare genetic variants can influence microRNA mediated post-transcriptional control, 
identifying a novel mechanism through which genetic predisposition might interact with 
environmental trigger to influence (auto)immunity and contribute to familial aggregation 
of T1D. Finally, we show that pivotal apoptosis pathways are affected in autoreactive T 
lymphocytes of T1D patients and that microRNA play a vital role in this, again indicating 
the importance of understanding of gene-gene and gene-environment interactions in 
the development of T1D. Yet, our work only covers a small part of the unknown and many 
aspects of the functional genetics of T1D remain to be addressed. As mentioned before, 
Figure 1. The immune reaction in Type 1 Diabetes – an update.  Adapted from B.O. Roep, 
Nature, 200737
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Expression of FAS and TRAIL is down-















GENERAL DISCUSSION AND SUMMARY
109
6
despite their valuable contribution thus far, larger GWAs studies are unlikely to aid this 
cause further, as potential new risk SNPs are expected to carry a very modest impact on 
disease susceptibility at best. With current technological advances and the advent of large 
sequencing centers, whole-genome sequencing, a technique that charts the complete 
genome of a single individual, has come within reach for academic researchers. Using 
whole-genome sequencing, future research will be able to overcome the limitations of 
GWAs by assessing al genetic variation within a single individual at once. At the same 
time this approach will generate an unparalleled amount of complex data. Data analysis, 
processing and statistics will most likely prove to be a bottleneck and new strategies for 
data-management will be required. From the cell-biological perspective of T1D research, 
optimization of single cell techniques that will allow for direct isolation and investigation 
of autoreactive T cells directly isolated from peripheral blood can eliminate cell culture 
artifacts and provide ‘clean’ data regarding the make-up of diabetogenic T cells and what 
distinguishes them from their non-diabetogenic counterparts. Further, direct isolations will 
allow for high-throughput analysis and remove the problem of limited sample availability 
currently complicating research.  Combined with improvements in big data analysis, this 
approach may prove invaluable in identifying molecular pathway involved in, or even 
preceding, β cell destruction. 
THERAPY
The cure and complete prevention of disease occurrence is the ultimate goal in medicine, 
but is also be the hardest goal to achieve. Fortunately, treatment modalities are constantly 
improving, allowing for better patient care in the interim. The future holds several promising 
outlooks for management of T1D, among which the artificial pancreas31, stem-cell derived 
(neo) β cells32 and promising immunotherapies.33-35 Recent myeloablative therapies with 
subsequent autologous stem cell transplantation that resulted in reduced, and in some cases 
very long-standing, insulin dependency demonstrate the power of immunotherapies and 
indicate that reprogramming the immune system may hold a potential cure for T1D 36.  Yet, 
the current approach subjects patients to high-risk conditions, using chemotherapies that 
cause temporary immunodeficiency and potentially life-threatening infections. Efforts are 
undertaken to try and achieve a subtler reprogramming of the unwanted immune reaction 
in a tissue-specific manner, thereby reducing risk of the procedure while maintaining its 
efficacy. As T1D is a heterogeneous disease, a (semi-) personalized approach is warranted 
for the selection of appropriate candidates and appropriate immune endpoints for these 
novel therapies. Detailed knowledge on the genetic background of affected individuals 
and their exposure to environmental risk modulators can be used to ‘match’ the patient to 
the correct treatment and reduce the unnecessary exposure of patients to therapies that 
are unlikely to provide them any benefit. Determining biomarkers that distinguish T1D 
patients from healthy individuals, genetic factors that can mediate environmental triggers 
to altered immune status and genetic variants that are causal for the association of T1D loci 
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with disease, as described in chapter 3, chapter 4 and chapter 5 of this thesis, will benefit 
patient selection and subsequent personalized treatment. Therefore, it is imperative that 
it remains a focus of attention alongside the development of novel therapeutic strategies. 
Currently several approaches using recombinant antibodies to immune-receptors, adoptive 
regulatory T cell therapy or vitamin D modified dendritic cells are in progress, and might 
prove efficacious and feasible options for the treatment of T1D. As with anything the proof 
of the pudding is in the eating, and results of these trials are eagerly awaited. 
Other strategies for combatting T1D aim to restore the insulin deficit directly, and 
thereby glycemic control, in T1D, rather than correcting the autoimmune response. 
The development of  automated, closed-loop systems that mimic the pancreas’ ability to 
sense glucose and release insulin according to need promises improved glycaemic control 
and increasing quality-of-life for T1D patients. Although this provides great promise in 
terms of improved quality of life and reduces the chance of acute complications of insulin 
replacement therapy, the artificial pancreas is not expected to fully reach the accuracy of 
endogenous β cells and will probably not completely prevent the long-term complications 
of T1D. Advances in (islet) transplantation have made replacement of lost β cells a realistic 
option for T1D patients, although as with all transplantations this approach suffers greatly 
from the shortage of donor organs and side-effects associated with immunosuppressive 
drugs that are, ironically, toxic to β-cells. Furthermore, as autoimmunity has a long-lived 
memory, the disease often recurs, leaving patients again dependent on exogenous 
insulin administration. The development of islet-protecting encapsulations, that allows for 
the free transfer of insulin while preventing the destruction of transplanted islets, promises 
better graft survival and transplant success. Concurrently, new sources of β cells are being 
investigated and with recent breakthroughs in differentiation of embryonic stem cells to 
(neo) beta-cells and establishment of immortalized β cell lines renewable sources of β cells 
appear within reach. 
With all of these approaches issues regarding safety, feasibility, efficacy and cost-
effectiveness need to be addressed and the continuing efforts of all those involved in 
overcoming T1D  will be needed for the years to come. 
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Type 1 diabetes mellitus (T1D) is een auto-immuunziekte waarbij β-cellen in de alvleesklier 
worden vernietigd door een nog onvolledig begrepen auto-immuunreactie.  β-  cellen 
zijn sterk gedifferentieerde neuro-endocriene cellen en de enige bron van het glucose-
regulerende hormoon insuline.  Het verlies van β-cellen leidt in patiënten met T1D tot 
een tekort aan absoluut insuline en daardoor aan inadequate glucoseregulatie. Zonder 
insuline zijn vet-, lever- en skeletspiercellen niet in staat glucose uit de bloedbaan op te 
nemen, wat zowel leidt tot een tekort aan de belangrijkste energiebron voor de perifere 
weefsels als tot een verhoogde bloedsuikerspiegel (hyperglycemie). Onder normale 
fysiologische omstandigheden wordt glucose door de nieren volledig uit de pre-urine 
geresorbeerd en komt het niet in de urine terecht. Bij ernstige hyperglycemie wordt het 
resorberend vermogen van de nieren voor glucose overtroffen en is glucose aantoonbaar 
in de urine (glycosurie). Dit fenomeen is verantwoordelijk voor de naam van T1D; diabetes 
mellitus betekent zoete doorstroom in het Grieks. Door het osmotische effect van glucose 
in de nierbuisjes veroorzaakt glycosurie een gelijktijdig verlies van grote hoeveelheden 
water en elektrolyten, wat het pathognomonische symptoom van veel urineren (polyurie) 
verklaart. Polyurie veroorzaakt op zijn beurt dehydratie en daarmee overdreven dorst wat 
het tweede  pathognomische  kenmerk van diabetes mellitus verklaart; polydipsia (veel 
drinken). In de diabetische toestand is glucose niet meer beschikbaar als energiebron 
voor perifere weefsels en stapt het lichaam over naar alternatieve mechanismen van 
energieproductie om vitale cellulaire processen te handhaven, zoals de oxidatie van 
vetzuren. Als bijproduct van de oxidatie van vetzuren worden zure ketonenlichamen. Het 
verlies van circulerend volume en elektrolyten die het gevolg zijn van de glycosurie, 
gecombineerd met de verhoogde productie van zure ketonenlichamen, kan leiden tot een 
levensbedreigende verstoring van het zuur-base evenwicht in het lichaam, een medische 
noodgeval dat wordt aangeduid met de diabetische ketoacidose. Als de metabole acidose 
niet snel wordt gecorrigeerd met intraveneuze toediening van vloeistoffen en exogeen 
insuline, leidt de aandoening tot een comateuze toestand van de patiënt en uiteindelijk 
de dood. 
In een van de oudste medische geschriften, de Ebers Papyrus,  wordt al een 
ziektebeeld met de typische kenmerken van T1D beschreven door de geneesheren uit 
het oude Egypte. Ondanks dat de ziekten al duizenden jaren bekend is, betekende het 
stellen van de diagnose een onherroepelijk doodvonnis voor de patiënt totdat Banting, 
Best en collegae in 1921 als eersten insuline wisten te isoleren uit de alvleesklier van 
een hond. Deze doorbraak baande de weg voor de eerste werkelijke behandeling van 
T1D, de insuline-vervangende therapie, waarmee een dodelijke ziekte veranderde in een 
chronische aandoening. Ondanks de vooruitgang van de kwaliteit van de behandeling, 
met name door de ontwikkeling van nieuwe insuline-analogen, verbetering van 
de toedieningsmethoden en de algehele verbetering van de gezondheidszorg, 
blijft insuline-vervangende therapie een symptomatische behandeling en geen 
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genezing. Patiënten met T1D blijven  levenslang afhankelijk van exogene insulinetoediening 
en lopen daarmee continue gevaar op de acute complicaties van deze therapie. Een 
teveel aan toegediende insuline leidt tot een te laag bloedsuikerniveau (hypoglycaemie) 
en indien ernstig genoeg een hypoglycemisch coma. Een tekort aan toegediende 
insuline leidt tot een diabetische ketoacidose. Beiden complicaties kennen een mogelijk 
dodelijke afloop. Naast de acute complicaties van hun behandeling lopen T1D patiënten 
het risico om op lange termijn complicaties als oog- hart- nier- en zenuwaandoeningen 
te ontwikkelen. Dit komt doordat insuline-vervangende therapie qua glucoseregulatie 
helaas de precisie mist van β-cellen. Door de behandeling zelf, die bestaat uit meerdere 
keren per dag glucose meten middels en het toediening van insuline, en de complicaties 
van hun behandeling, ervaren T1D patiënten een verminderde kwaliteit van leven 
evenals een verminderde levensverwachting.  Opheldering van het ziekteproces van 
T1D is noodzakelijk voor de ontwikkeling van een definitieve genezing en daarmee een 
gewild doel in de moderne geneeskunde. Momenteel wordt het ziekteproces van T1D 
nog onvolledig begrepen, maar bekend is dat zowel omgevingsfactoren als genetische 
eigenschappen bijdragen aan het risico om de ziekte te ontwikkelen.  Hierbij is er een 
grote heterogeniteit in ziekteprogressie, waarmee het waarschijnlijk is dat er waarschijnlijk 
verschillende optimale therapieën bestaan voor verschillende patiënten. Het ophelderen 
van de genetische mechanismen die bij de ziekteontwikkeling betrokken zijn zal bijdragen 
aan gepersonaliseerde geneeskunde en is belangrijk voor de ontwikkeling van nieuwe 
therapieën en een mogelijke curatieve behandeling. Het doel van dit proefschrift is 
hieraan bij te dragen door nieuwe inzichten te geven in zowel transcriptionele als post-
transcriptionele genregulatie in het ziekteproces van T1D. 
Hoofdstuk 2
In hoofdstuk 2 van dit proefschrift wordt de rol van differentiële splicing van G6PC2 tussen 
alvleesklier en de thymus bij de ontwikkeling van auto-immuniteit beschreven. Het gen 
G6PC2 codeert voor het eiwit islet-specific glucose-6-posphatase catalytic subunit-related 
protein (IGRP), een bekend doelwit van autoreactieve CD8+ T cellen in patiënten met T1D. In 
een eerdere wetenschappelijke publicatie werd gesuggereerd dat bepaalde isovormen 
van G6PC2, met name degene die exon 3 en 4 van G6PC2 bevatten, niet in de thymus 
tot expressie komen en dat dit in bijdraagt aan de autoimmuun-reactie tegen IGRP. Om te 
onderzoeken wat het daadwerkelijk effect van differentiële splicing op auto-immuniteit zou 
zijn hebben we eerst  isovorm-specifieke primers voor G6PC2 ontwikkeld om de expressie 
van G6PC2 in de thymus en alvleesklier te kunnen kwantificeren. Hiermee toonden we 
aan dat, in tegenstelling tot eerdere aannames, alle  conventionele G6PC2  isovormen 
in de thymus te vinden zijn, al ware het in aanzienlijk lagere hoeveelheden dan in 
de alvleesklier. Vervolgens hebben we de  autoreactiviteit  tegen de verschillende 
G6PC2 isovormen onderzocht door het niveau van IGRP-specifieke autoantilichamen en 




bloed van de patiënten en gezonde personen te bepalen.  Ondanks dat T-cellen die 
reactief zijn tegen IGRP-afgeleide peptiden gemakkelijk gedetecteerd konden worden 
in het perifere bloed van zowel gezonde individuen als T1D patiënten, wat op zichzelf 
suggereert dat negatieve selectie van reactieve T-lymfocyten van IGRP onvolledig is, 
werd er geen significant verschil gevonden tussen T1D patiënten en gezonde individuen. 
Deze bevinding impliceert dat de defecte negatieve selectie van IGRP-reactieve 
T-cellen opzichzelfstaand onvoldoende is voor de ontwikkeling van T1D. Concluderend 
corrigeerden we een eerdere aanname dat er sprake is van kwalitatief verschil in splicing 
van G6PC2 tussen alvleesklier en thymus. Verder toonden we aan dat de negatieve selectie 
van IGRP specifieke T cellen inherent incompleet is, maar geen directe gevolgen heeft 
voor de ontwikkeling van auto-immuniteit in het kader van T1D. 
Hoofdstuk 3
Zoals reeds beschreven werd in hoofdstuk 2 worden auto-reactieve T-cellen frequent 
aangetroffen in het perifere bloed van gezonde personen.  Een mogelijk verschil 
tussen niet-aangedane individuen en patiënten zou de capaciteit van hun regulerende 
T-cellen (T-reg cellen) kunnen zijn om auto-immuunresponsen te dempen of überhaupt 
te voorkomen dat ze plaatsvinden. Zowel verminderde activiteit van T-reg  cellen, als 
een verhoogde weerstand  auto-reactieve T-cellen voor regulatie zijn beschreven voor 
verschillende auto-immuunziekten, waaronder T1D.  In hoofdstuk  3  van dit proefschrift 
vergeleken we twee auto-reactieve T-cel klonen geïsoleerd uit een T1D patiënt met een 
auto-reactieve T-cel kloon geïsoleerd uit een gezond individu. Daarbij constateerden 
we dat auto-reactieve T-cellen van het gezonde individu maar een beperkt aantal keer 
konden worden gestimuleerd totdat ze stopten met vermenigvuldigen, een kenmerk dat 
niet waargenomen werd in auto-reactieve T-cellen van de T1D patiënt.  Transcriptoom 
analyse van de verschillende T-cel klonen onthulde in de T-cellen van de T1D patiënt 
gereduceerde expressie van TRAIL, TRAIL-R2, FAS en FASLG, genen betrokken bij het 
proces van apoptose (gereguleerde celdood). De gereduceerde expressie van deze genen 
ging gepaard met verhoogde expressie van een drietal microRNA’s, moleculen met een 
belangrijke rol in de post-transcriptionele regulatie van genexpressie. Computermodellen 
voorspelden dat de microRNA’s miR-98, miR-23b en miR-590-5p betrokken waren bij 
de regulatie van TRAIL, TRAIL-R2, FAS en FASLG.  Eerst leverden we het bewijs dat 
de microRNA’s miR-98, miR-23b en miR-590-5p daadwerkelijk de genen TRAIL, TRAIL-R2, 
FAS en FASLG reguleerden met behulp van dual-luciferase reporter assays. Vervolgens 
transfecteerden we de verschillende microRNA’s in primaire T-cellen waarbij een significant 
verminderde expressie van FAS- en TRAIL-mRNA-expressie werd waargenomen. Hiermee 
werd de functionele relevantie van deze microRNA’s bij de weerstand van auto-reactieve 
T-cellen tegen apoptose onderstreept.  Omdat de expressie van microRNA’s beïnvloed 
kan worden door milieufactoren, zou verdere analyse van het microRNA transcriptoom 
van auto-reactieve cellen mogelijk nieuwe therapeutische opties kunnen verschaffen en 
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inzicht kunnen verschaffen in omgevingsfactoren die betrokken zijn bij de ontwikkeling 
van T1D. Samenvattend toonden we aan dat de verschillen in proliferatieve capaciteit 
tussen auto-reactieve T-cellen van gezonde individuen en patiënten samenhangt met 
verschillen in expressie van pro-apoptotische genen en de post-transcriptionele factoren 
die ze reguleren.
Hoofdstuk 4
In hoofdstuk 4  van dit proefschrift onderzochten we de mogelijke interactie tussen 
zeldzame genetische varianten en functionaliteit van microRNA’s.  Genoom brede 
associatiestudies (GWA’s) hebben onze kennis over de relatie van genomische gebieden 
en het voorkomen van (auto-immuun)ziekten sterk vergroot.  Echter, zelfs als men alle 
geverifieerde ziektegeassocieerde genomische regio’s van T1D in aanmerking neem, 
is het onmogelijk de erfelijkheid van T1D volledig te verklaren.  GWA’s zijn ontworpen 
voor de detectie van frequent voorkomende genvarianten, zo geheten single nucleotide 
polymorphisms (SNP’s). Daarom kunnen zeldzame SNP’s en structurele DNA variaties als 
inserties, deleties en duplicaties niet geanalyseerd worden met de huidige generatie 
GWA’s. Er wordt daarpm verondersteld dat de ‘ontbrekende erfelijkheid’ van complexe 
ziekten als T1D kan worden verklaard door zeldzame en structurele genvariaties. In een 
proof-of-concept-studie hebben we zeldzame polymorfismen in T1D-risicogenen in silico 
onderzocht op hun capaciteit om post-transcriptionele genregulatie te beïnvloeden 
door de binding van microRNA’s te veranderen. Door middel van mutagenese testten 
we deze voorspellingen en toonden in vitro aan dat zeldzame SNP’s, welke we miRSNP’s 
noemen, het vermogen hebben microRNA-gemedieerde genregulatie te beïnvloeden door 
ofwel een bindingplaats voor microRNA te creëren, dan wel deze te verstoren. Hiermee 
geven we bewijs voor een nieuw mechanisme waarmee zeldzame genvariaties het risico 
op het ontwikkelen van T1D kunnen beïnvloeden. Omdat de expressie van microRNA’s 
beïnvloed kan worden door omgevingsfactoren, omschrijft deze studie tevens een manier 
waarop omgevingsfactoren selectief voor individuen met bepaalde DNA eigenschappen 
het risico op T1D kunnen vergroten. Echter zal er eerst meer bekend moeten worden over 
de exacte manier waarop de expressie van microRNA’s zelf gereguleerd wordt voordat er 
duidelijke verbanden uit getrokken kunnen worden tussen omgevingsfactoren, zeldzame 
DNA variaties en de ontwikkeling van T1D.
Hoofdstuk 5
Cytotoxische T-lymfocytenantigen-4 (CTLA-4) is een oppervlaktemolecuul aanwezig op 
geactiveerde T-cellen dat de T-celreceptorsignalering remt. Er wordt gedacht dat variaties 
binnen het  CTLA4-gen het risico op de ontwikkeling van  auto-reactieve  T-cellen, en 
daarmee het risico op auto-immuunziekten als T1D, vergroot. Het CTLA4 locus ligt op een 
genomisch gebied dat als een van de eerste werd geassocieerd met gevoeligheid voor 




deze associatie, evenals de moleculaire mechanismen die door deze de variatie beïnvloed 
werden, onbekend. Recente studies hebben aangetoond dat de regio gekenmerkt door 
de SNP CT60 (rs3087243) fungeert als risicofactor. Het CT60 polymorfisme bevindt zich 
echter niet in het CTLA4-gen, maar ligt downstream van het gen in een niet-coderend 
gebied. De manier waarop deze variatie de functie van het CTLA4-gen zou beïnvloeden is 
dan ook niet bekend. In hoofdstuk 5 van dit proefschrift tonen we aan dat een structurele 
genvariant, namelijk  de (AT)n  microsatelliet  die zich in de 3’-untranslated region (UTR) 
van CTLA4 bevindt,   oorzakelijk is voor de genetische associatie van  CTLA4  met T1D 
gevoeligheid. Allereerst onderzochten we de associatie van de CTLA4 (AT)n microsatelliet 
met de T1D risicomarker CT60.  Deze analyse toonde aan dat CT60 status en (AT)
n  lengte zeer nauw samenhingen. CTLA4  allelen met langere (AT)n  elementen kwamen 
alleen gekoppeld met het risico haplotype CT60G voor.  Omgekeerd werd het 
beschermende CT60A haplotype vaker gezien in samenhang met wildtype, korte  (AT)
n elementen. Derhalve correleerden lange (AT)n elementen direct met een verhoogd risico 
op β-cel auto-immuniteit. In auto-reactieve T-cellijnen associeerden langere microsatelliet 
lengten met een significant verminderde CTLA4 genexpressie. Tevens leidde de transfectie 
van een lange (AT)n microsatelliet in vitro tot verlaagde reporter mRNA-expressie van een 
reportergen. Het directe effect van de lengte van de (AT)n microsatelliet op genexpressie, 
in combinatie met de uitzonderlijk sterke correlatie met CT60 status impliceert een 
causale rol voor de (AT) n microsatelliet in de genetische associatie van het CTLA4 gebied 
met T1D gevoeligheid. Tevens geeft deze een verklaring voor het mechanisme waarmee 
de variatie de gevoeligheid voor T1D verhoogd, namelijk door de expressie van het 
immuunregulerende gen CTLA4 te verminderen.
TOEKOMSTPERSPECTIEVEN
Onderzoek
De afgelopen decennia hebben (bio)medische wetenschappers een overvloed aan 
informatie over de genetica van complexe ziekten zoals T1D vergaard. Inzicht krijgen in 
hoe genvarianten ziektegevoeligheid beïnvloeden en de interactie tussen milieu, genetica 
en immunologie bepalen, zijn de volgende hindernissen om te nemen. Het bereiken van 
deze doelen kan bijdragen aan het voorspellen van ziekteprogressie, ontwerpen van 
nieuwe behandelmethoden en de ontwikkeling van “gepersonaliseerde geneeskunde”.
Dit werk heeft slechts een klein deel van de vele aspecten van de functionele genetica van 
T1D behandeld. Met recente technologische vooruitgangen is whole genome sequencing, 
een techniek die het volledige genoom van een enkel individu compleet in kaart brengt, 
binnen handbereik gekomen voor onderzoekers.  In de nabije toekomst zal het hiermee 
mogelijk zijn álle genetische variatie van een individu tegelijkertijd te bepalen, en daarmee 
de beperkingen van GWA’s wegnemen. Tegelijkertijd zal deze aanpak een ongeëvenaarde 
hoeveelheid complexe data genereren.  Waarschijnlijk zullen gegevensanalyse 
en -verwerking samen met de statistische analyse hiervan een volgend knelpunt zijn. 
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Nieuwe strategieën voor gegevensbeheer en analyse zijn dus noodzakelijk. Uit 
de celbiologisch perspectief zal het onderzoek naar T1D hoogstwaarschijnlijk profiteren 
van zogeheten single-cell technieken die momenteel (door)ontwikkelt worden. Deze 
technieken maken isolatie en analyse van auto-reactieve cellen direct uit het bloed van 
patiënten mogelijk en verminderen daarmee de kans op artefacten die komen kijken bij 
de, nu nog noodzakelijke, celkweken. Bovendien biedt het direct isoleren en analyseren van 
auto-reactieve cellen de mogelijkheid voor “high-throughput” analyses. Gecombineerd 
met verbeteringen in data-analyse kan deze aanpak van onschatbare waarde zijn bij het 
identificeren van de moleculaire mechanismen die betrokken zijn bij, of mogelijk zelfs 
diegene die voorafgaan aan, β-celvernietiging.
Behandeling
Momenteel zijn er veelbelovende vooruitzichten voor de behandeling van T1D, 
waaronder de kunstmatige alvleesklier, van stamcellen afgeleide (neo) β-cellen en 
immuuntherapieën.  Recente  myeloablatieve  therapieën gevolgd door latere autologe 
stamceltransplantatie resulteerden in gereduceerde insulinebehoefte en in sommige 
gevallen zelfs langdurige insulineonafhankelijkheid. Deze aanpak stelt patiënten 
echter bloot aan hoge risico’s, aangezien chemotherapie een noodzakelijk van deze 
behandeling is. Momenteel wordt er in verschillende onderzoekgroepen gewerkt 
aan een subtielere manier de ongewenste immuunreactie op een weefselspecifieke 
manier te “herprogrammeren”. Aangezien T1D een heterogene ziekte is, is een (semi-) 
gepersonaliseerde benadering in de toekomst gerechtvaardigd  bij de keuze voor 
de geschikte (immuun)therapie. Gedetailleerde kennis over de genetische achtergrond 
en de persoonlijke blootstelling van omgevingsfactoren kan worden gebruikt om per 
patiënt de juiste behandeling te kiezen en kan onnodige blootstelling aan ineffectieve 
therapieën voorkomen. Onderzoek zoals beschreven in dit proefschrift heeft de potentie 
om gepersonaliseerde behandeling ten goede komen.  Derhalve is het van essentieel 
belang dat naast de ontwikkeling van nieuwe therapeutische strategieën in de toekomst, 
ook aandacht wordt besteed aan de (functionele) genetica van T1D. 
Naast onderzoeken die de genezing van T1D nastreven zijn er verschillende initiatieven 
om de huidige behandeling van T1D te verbeteren. De ontwikkeling van geautomatiseerde 
systemen met een “closed-loop”, die het vermogen van de alvleesklier om zelfstandig 
glucose te detecteren en de benodigde insuline vrij te geven nabootsen, belooft 
verbeterde glycemische controle en verhoogde levenskwaliteit voor T1D patiënten. Hoewel 
de kunstmatige alvleesklier de nauwkeurigheid van endogene β-cellen waarschijnlijk 
niet volledig zal bereiken en daarmee dus ook de lange-termijncomplicaties niet geheel 
zal kunnen voorkomen heeft deze ontwikkeling wel de potentie om de levenskwaliteit 
van T1D te verbeteren en de risico’s op acute complicaties van insulinetoediening te 
reduceren. Transplantatie van β-cel bevattende eilandjes van Langerhans lijkt door 




bij alle transplantaties lijdt deze aanpak sterk onder het tekort aan donororganen en 
bijwerkingen van de afweeronderdrukkende geneesmiddelen die noodzakelijk zijn na 
transplantatie. De ontwikkeling van beschermende capsules die de getransplanteerde 
eilandjes van Langerhans beschermen, belooft betere transplantaatoverleving en daarmee 
succes.  Tegelijkertijd worden er momenteel nieuwe bronnen van β-cellen onderzocht 
en met recente doorbraken in de differentiatie van embryonale stamcellen naar (neo) 
β -cellen en de ontwikkeling van kweekbare β-cellijnen komen hernieuwbare bronnen van 
β-cellen binnen bereik.
Bij al deze benaderingen is de samenwerking tussen (bio)medici, industrie, overheid 
en vrijwilligers essentieel om problemen op het gebied van veiligheid, haalbaarheid, 
efficiëntie en kosteneffectiviteit aan te pakken en zal de continue inspanning van alle 
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